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ABSTRACT
Endothelial function is an indicator and predictor of cardiovascular health. Mechanisms
of endothelial function in premenopausal women remain unclear, including across hormonal
state or phase, as well as in comparison with men. This dissertation includes four projects assessing cutaneous microvascular and endothelial function. The overall purpose is to investigate
mechanisms of endothelial function and nitric oxide (NO) bioavailability in premenopausal
women, with a specific focus on the impact of monophasic, combined oral contraceptive pills
(OCP). Major findings are as follows. 1) During respective low hormone (LH) phases, NO-dependent dilation is greater in women using OCP (74±11 %NO) than naturally cycling (NC)
women (NC women, 52±14 %NO; p<0.01) and men (52 ±11 %NO, p<0.01). 2) OCP phase does
not affect overall endothelium-dependent vasodilation (LH: 59±23 %CVCmax; high hormone,
HH: 56±25 %CVCmax). 3) OCP phase affects mechanisms underlying endothelial function
(p=0.03), primarily an interaction between the NO (control LH, 72±13 %NO; control HH, 62±16

%NO) and cyclooxygenase (COX; COX inhibition LH, 63±19 %NO; COX inhibition HH,
75±12 %NO) pathways. Further, women using OCP may have a greater interdependence on endothelial-derived hyperpolarizing factors to elicit vasodilation (65-69%) than previously reported
findings in young, mixed-sex cohorts. 4) Women using OCP demonstrate a basal presence of
COX-derived vasoconstrictors (baseline: control, 16±10 %CVCmax; COX inhibition, 27±11
%CVCmax), previously not demonstrated in young, mixed-sex cohorts. 5) A case study revealed
OCP use may reduce endothelial function, demonstrated by substantially improved endotheliumdependent vasodilation following OCP cessation (during use: 42±10 %CVCmax; after cessation:
63±10 %CVCmax). Collectively, these data suggest women in LH phases of the natural menstrual
cycle and various exogenous hormone states may not have equivalent endothelial function,
which is important for experimental design. Additionally, these data suggest the withdrawal of
exogenous hormones (i.e., the OCP LH phase or cessation of use) improves endothelial function
and/or NO bioavailability. Therefore, OCP use appears to alter mediating mechanisms in the vasculature, which may contribute to cardiovascular health in women.
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1 THE PROBLEM
Endothelial function is an essential indicator and predictor of cardiovascular (CV) health
and disease1. Microvascular vasodilation within the skin is a marker of systemic microvascular
function and can be easily evaluated with minimally invasive assessment techniques2. To date,
mechanisms of endothelial function in premenopausal women remain unclear, especially under
varying hormonal states, hormonal phases, or compared with men of similar age. A historical
over-reliance on men in clinical CV research has contributed to this discrepancy in knowledge;
thus, more targeted research regarding women’s CV health is necessary. This dissertation is
aimed to investigate the mechanisms underlying endothelial function in premenopausal women
and explore possible contributing factors. Overall, findings from this dissertation may allow
greater understanding of microvascular and endothelial function in premenopausal women. This
may facilitate translation to clinical practice and assist in improving women’s CV health and
care. This chapter will introduce the context of this dissertation by briefly discussing key background information and gaps in the literature this research intends to address. This chapter will
also define the guiding research questions, aims, and hypotheses. Finally, this chapter will discuss the potential value of knowledge to be gained and the limitations/delimitations of the completed studies.
The history of placing less importance on women’s biology in research, including CV
physiology and pathophysiology, may underlie shortcomings in prevention, diagnosis, and treatment of CV diseases (CVD) in women today. Despite the misconception that women are ‘protected’ from CVD, women have higher prevalence and mortality rates of several CVDs than
men, including stroke and myocardial infarction (MI)3, 4. The National Institutes of Health implemented policy to include sex as a biological variable in biomedical and clinical research in
20165. While research in women has since increased overall, and certainly in areas investigating
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the menopausal transition or pregnancy-related complications, gaps remain in the basic understanding of vascular physiology in premenopausal women.
It is well-established that sex hormones have effects on the vasculature, including actions
on endothelial cells6, 7. Importantly, this includes effects on one of the primary endothelium-dependent pathways, the nitric oxide (NO) pathway6, 8, 9. However, in vitro data indicate that endogenous and exogenous hormones, namely, estradiol versus ethinyl estradiol (EE), respectively,
may not exhibit identical bioactivity8, 9. The effects of endogenous progesterone or exogenous
progestin (both independently and in combination with estrogens) are less elucidated6. This suggests hormonal exposure (endogenous versus exogenous) may differentially affect vascular
and/or endothelial function.
Women using oral contraceptive pills (OCP) display elevated markers of oxidative stress
and inflammation compared with women who do not use OCP10-12. Both oxidative stress and inflammation can negatively affect endothelial function and NO bioavailability13-15. Additionally,
OCP use is associated with increased risk of thrombosis16, 17, which would further suggest endothelial dysfunction. However, previous studies assessing in vivo conduit vessel endothelial function in naturally cycling (NC) women and women using OCP have yielded inconsistent results,
with studies suggesting increases, decreases, or no changes in endothelial function between these
subgroups of premenopausal women7, 18-21.
The microvasculature may be a more sensitive vascular bed to assess functional changes,
as microvascular dysfunction often precedes conduit vessel dysfunction22-25. When considering
in vivo microvascular assessments, there is indirect indication of reduced NO bioavailability in
NC women during their low hormone phase (i.e., menstrual/early follicular, M/EF, respectively)
compared with women using OCP in their respective low hormone phase (i.e., during placebo
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pills or the pill-free week of OCP use)26, 27. There is also support for opposite relationships between microvascular function and circulating endogenous or exogenous hormone levels (i.e.,
lower endogenous hormone phases yield lower microvascular vasodilation while lower exogenous hormone phases yield higher microvascular vasodilation, and vice versa with high hormone
phases)28, 29. Therefore, the decline in circulating exogenous hormones during the low hormone
phase of OCP use may induce relative reductions in inflammation and/or oxidative stress that
temporarily alleviate endothelial distress, allowing greater NO bioavailability and vasodilation
responses. However, there are several endothelium-dependent pathways (which interact with
each other), and it is currently unknown how hormonal exposure (i.e., NC or using OCP) or hormonal phase (i.e., low or high hormone phases) affect activity of these underlying pathways.
There are distinct gaps within the literature regarding in vivo microvascular and endothelial function in premenopausal women, including between sex differences (i.e., premenopausal
women versus men) and within sex differences (i.e., changes in hormonal exposure or hormonal
phase within premenopausal women). This dissertation also addresses several topics concerning
OCP use and vascular physiology in premenopausal women7, including the need for well-controlled phasic analyses, microvascular analyses, and mechanistic insight into the vascular effects
of OCP use and OCP cessation. Further, this dissertation provides preliminary perspective on the
influence of lifestyle behaviors on endothelial function in premenopausal women using OCP. For
these reasons, this dissertation is uniquely positioned to guide multiple currently un- or underinformed aspects of vascular physiology in premenopausal women.
Research Questions
The guiding research questions of this dissertation are five-fold.
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1. Is cutaneous microvascular endothelial function and NO-dependent vasodilation similar between women in low hormone phases and men?
2. Is cutaneous microvascular endothelial function and NO-dependent vasodilation similar between NC women and women using monophasic, combined OCP when tested during their
respective low hormone phases?
3. In women using OCP, do the mechanistic pathways regulating cutaneous microvascular endothelial function differ between low and high hormone phases?
4. In women using OCP, do lifestyle behaviors or characteristic/behavioral aspects of OCP use
correlate with cutaneous microvascular endothelial function or NO-dependent vasodilation?
5. How does cessation of OCP use affect cutaneous microvascular endothelial function or NOdependent vasodilation?
Purpose
The overarching purpose of this research was to assess cutaneous microvascular endothelial function and NO bioavailability in premenopausal women who are either NC or using
OCP. This dissertation includes five specific aims.
Specific aim 1 was to characterize cutaneous microvascular endothelium-dependent and
NO-dependent vasodilation between women in low hormone phases of their respective hormonal
state (either NC or using OCP) and men of similar age. Specific aim 2 was to compare endothelium-dependent and NO-dependent vasodilation between subgroups of NC women, women using
OCP, and men, in a planned subgroup analysis. We hypothesized 1) the magnitude of endothelium-dependent vasodilation would be similar between women in low hormone phases and men,
2) NO-dependent vasodilation would be similar between women in low hormone phases com-
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pared with men, 3) endothelium-dependent vasodilation would be similar between the two subgroups of women (i.e., NC women and women using OCP), and 4) NO-dependent vasodilation
would be greater in women using OCP compared with NC women in their respective low hormone phases.
Specific aim 3 was to assess the effect of OCP phase (either low hormone or high hormone) on mechanisms underlying cutaneous microvascular endothelial function in premenopausal women using OCP, including the NO pathway, cyclooxygenase (COX) pathway, and endothelial-derived hyperpolarizing factor (EDHF) pathways. We hypothesized 1) overall endothelium-dependent vasodilation would be similar between the low hormone and high hormone
phase of OCP use, 2) NO-dependent vasodilation would be reduced during the high hormone
phase of OCP use compared with the low hormone phase, 3) EDHF-dependent vasodilation
would be increased during the high hormone phase of OCP use compared with the low hormone
phase, and 4) COX inhibition would increase baseline blood flow and NO-dependent vasodilation, but not impact endothelium-dependent vasodilation, in both phases of OCP use.
Specific aim 4 was an exploratory aim to evaluate the relative impact of potential correlates of cutaneous microvascular endothelial function and NO bioavailability in premenopausal
women using OCP. The potential impact of lifestyle behaviors and characteristic/behavioral aspects of OCP use (i.e., duration of use) were assessed. We hypothesized the magnitude of endothelium-dependent and NO-dependent vasodilation would 1) directly correlate with hours of
sleep, hours of moderate and vigorous physical activity, and quantity of dietary intake of vasculo-protective foods, 2) inversely correlate with self-reported psychological stress, and 3) inversely correlate with duration of OCP use.
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Specific aim 5 was an exploratory aim (investigated via case study) to assess the impact
of cessation of OCP use on cutaneous microvascular endothelial function and NO bioavailability
in one young, healthy, premenopausal woman. We hypothesized the 1) magnitude of endothelium-dependent vasodilation would be greater following cessation of OCP use, and 2) there
would be greater variability in NO-dependent vasodilation when NC compared with using OCP.
Significance of the Study
This dissertation is aimed to increase the understanding of microvascular and endothelial
function in premenopausal women. Premenopausal women are exposed to a variety of hormonal
states and phases throughout the lifespan. In addition to cyclic endogenous hormone changes,
many women are exposed to exogenous hormones during premenopausal years, often via the use
of OCP. Use of OCP is associated with increased risk of thrombosis, hypertension, stroke, and
myocardial infarction (MI)16, 17, 30. These conditions all suggest alterations to vascular and/or endothelial function. However, mechanistic evaluation of microvascular and endothelial function
across these exposures in premenopausal women and compared with men is lacking. Overall,
limited research regarding CV physiology in otherwise healthy, premenopausal women may indirectly pose a public health problem by limiting the ability to fully understand, integrate, and
apply knowledge gained from physiological data collected in other sub-populations of women.
Assumptions and Limitations
Assumptions and limitations of the studies included in this dissertation are as follows.
1) Health status via blood profile, including fasting blood glucose and lipid panel, was
not assessed in any of the participants included.
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2) Women using any monophasic, combination OCP were allowed to participate in these
studies. Therefore, OCPs used by women included in the following studies varied by progestin
generation and dosage, EE dosage, and OCP brand.
3) Day/phase of the natural menstrual cycle or OCP use was self-reported. Therefore,
these studies operated under the assumption that included women were honest about day/phase
of their natural menstrual cycle or OCP use. Additionally, experimental design relied on the assumption that women using OCP were compliant with their pill administration (i.e., not missing
pills) and administered their pills/doses at consistent times across days.
4) Women did not undergo cycle tracking prior to experimental testing. However, NC
women were only included in Project 1, where they were tested during days (d) 2-5 of the natural
menstrual cycle.
5) Self-report data regarding lifestyle behaviors (i.e., physical activity, sleep, dietary intake, and stress) may be subject to recall bias and were not confirmed by objective assessment.
6) In regard to Project 4, this was a case study by design. As such, there is low external
validity, considering this singular account. Therefore, conclusions should be drawn from this
data with caution. Further limitations (and strengths) associated with this case study will be discussed below in the Discussion portion of this dissertation.
Delimitations
Delimitations of the studies included in this dissertation are as follows and correspond
with numbering of the above limitations/assumptions.
1) All included participants confirmed health status via health history questionnaire, were
normotensive, and did not use any medications (except OCP in appropriate samples).
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2) The included experiments were designed to assess the general impact of hormonal
phase (low or high hormone) of monophasic, combination OCP use on microvascular and endothelial function. Therefore, the intent of these studies was not to assess the impact of OCP generation, dose, or brand on primary outcome variables, so we did not base inclusion on these parameters. It is common within the field of cutaneous microvascular research to include women using
any variety of monophasic, combined OCP; therefore, this choice in participant inclusion reflects
this current practice within the field. Further, previous literature demonstrating increased oxidative stress and inflammatory biomarkers in women using OCPs compared with NC women included women using monophasic, combination OCP of any generation, dosage, and brand10-12.
Studies in this dissertation were designed with this practical relevance and key evidence in mind.
Notwithstanding, there are previous findings that suggest differences in conduit vessel endothelial function between OCP generation and EE dose or ratio18-20, and thus more specific investigation into these targeted research questions is warranted in the future.
3) All women verbally confirmed date of NC or OCP cycle. This was commonly confirmed by self-reported cycle tracking via mobile-based apps or presentation of current pill pack.
4) The M/EF phase of the NC is an easily self-tracked hormonal phase. All NC women
verbally confirmed current day of NC at experimental visits, which was commonly confirmed by
self-reported cycle tracking via mobile-based apps.
5) All women participating in the project addressing Specific Aim 4 were told before
each visit that they would be asked to recall aspects of certain lifestyle behaviors from 7 days
prior to the visit. The initial collection of these data was aimed to preliminarily assess associations with endothelium-dependent and NO-dependent vasodilation measurements. Therefore,
more specific investigation into these targeted research questions may be warranted in the future.
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6) In regard to Project 4, this is the first documented case study assessing endothelial
function across the transition of OCP cessation following long-term OCP use. While external validity is low based on this singular account, we believe this case study demonstrates relevant and
important information that has previously been undocumented. Further strengths (and limitations) associated with this case study will be discussed below in the Discussion portion of this
dissertation.
Overview of the Study
This dissertation is aimed to inform cutaneous microvascular function (both endotheliumdependent and NO-dependent mechanisms) in premenopausal women, with a specific focus on
the role of monophasic, combination OCP use. Throughout projects within this dissertation,
comparisons will be made within and between subgroups of NC women, women using OCP, and
similar age men. All comparisons were based on a priori sample size calculations to achieve ≥
80% power at an alpha level of 0.05. Included participants were all young and healthy. Cutaneous microvascular function has been assessed using a three-component instrumentation of laserDoppler flowmetry probes, local heating units, and intradermal microdialysis fibers. Microvascular vasodilation has been provoked via a rapid local heating protocol of the skin to 39°C. The
contribution of specific mechanistic pathways has been dissected via perfusion of the following
pharmacological agents through intradermal microdialysis fibers: 1) N-nitro-L-arginine methyl
ester (L-NAME), to assess the NO pathway, 2) ketorolac, to assess the COX pathway, and 3) tetraethylammonium (TEA), to assess EDHF-dependent pathways.
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2 REVIEW OF THE LITERATURE
The National Institutes of Health implemented policy to include sex as a biological variable in biomedical and clinical research in 20165. This policy followed years of heavily disproportionate reliance on male subjects (human and animal), including in CV physiology research. Today, there is a gap in understanding of CV physiology and pathophysiology in premenopausal
women, both within subgroups of women and compared with age-matched men. Given the state
of the body of literature regarding sex-specific attributes of CV physiology and pathophysiology,
more research in women’s CV health is necessary, including the basic understanding of vascular
mechanisms in premenopausal women.
Cardiovascular Health in Women
The risk of CVD is often underestimated in women compared with men, likely due to a
misconception that women are protected from CVD. However, CVD is the leading cause of
death in both men and women, with a similar percentage of total deaths attributable to CVD in
men and women (average 30.6% vs. 30.4%, respectively) in the United States3. Women experience increased mortality from several distinct CVDs, including MI, stroke, heart failure, and peripheral artery disease, compared with men3, 31. More importantly yet, younger women (<50
years old) have a 2-fold greater MI mortality rate compared with men or older women4. This discrepancy highlights current shortcomings in the understanding of CV physiology and pathophysiology in women, but namely younger, premenopausal women.
The literature suggests sex-specific CVD pathogenesis. Overall, CVD is atherosclerotic,
occlusive, and more extensive in larger vessels in men32, while CVD is more likely to be nonobstructive and include microvascular dysfunction in women33-36. Indeed, female sex (OR: 2.8)
and younger age (OR per 10-year decrease: 1.5) are the main independent predictors of non-ob-
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structive CVD diagnosis37. Angina, the main symptom of myocardial ischemia, also presents differently between men and women. Angina is less likely to be associated with obstructive CVD
(i.e., atherosclerosis) in women compared with men38, 39. This suggests angina is more often
caused by a reduction of myocardial blood flow due to vasoconstriction of surrounding blood
vessels (i.e., vasospasm; referred to as variant angina)40 in women compared with men. The underappreciation of these differences in the basic science of CV pathophysiology between sexes
has repercussions in clinical practice. For instance, CVD diagnosis relies on traditional methods
to provoke ischemia or symptoms arising from obstructive coronary atherosclerotic plaques31;
however, greater likelihood of non-obstructive etiology in women compared with men leaves
women often un- or misdiagnosed, and thus, un- or undertreated. It is currently not well-understood how sex differences contribute to the vulnerability of vascular bed (i.e., macro- versus micro-vessels) to risk factors across the lifespan.
Women, especially younger women, display elevated prevalence of other vascular conditions associated with heightened vascular reactivity, including Raynaud’s syndrome41, migraine42, and transient cerebral vasospasm (also referred to as reversible cerebral vasoconstriction syndrome)43. Interestingly, in premenopausal women, variant angina and myocardial ischemia present quicker and more severely in response to stress during phases of the menstrual
cycle when circulating levels of the primary sex hormones, estrogen and progesterone, are low
(i.e., during the M/EF phase)44, 45. Premenopausal women with variant angina also document
greater frequency of unprovoked ischemic episodes during low hormone phases45. Therefore,
acute changes in circulating concentrations of sex hormones may portray clinically relevant vascular and endothelial effects in women, including alterations in vascular reactivity.
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Women are exposed to several hormonal states across the lifespan, through pre-menarche, premenopausal, (possibly) pregnant and post-partum, peri-menopausal, and finally postmenopausal phases. However, during premenopausal years, circulating concentrations of sex
hormones also vary in a monthly cycle. If not complicated enough, women are also often exposed to various forms of exogenous hormones, including hormonal contraceptives, such as
OCP. Exogenous hormone exposure (i.e., OCP use) may place women uniquely at risk for CV
complications compared with men. There are links between OCP use and increased lifetime hypertension risk (relative risk, RR: 1.7530) and increased risk of venous (odds ratio, OR: 2.7816)
and arterial (stroke, RR: 1.7; MI, RR: 1.617) thromboembolism. These outcomes suggest the vasculature is susceptible to negative effects of OCP. Indeed, OCP use is linked to elevated inflammation and oxidative stress10-12, which are both common features in endothelial dysfunction discretely46-50 and in conjunction with CVD pathogenesis14, 15. However, understanding of the impact of hormonal phase and OCP use on in vivo vascular and endothelial function remains unclear.
Lifestyle behaviors, such as physical activity, sleep, dietary intake, and stress, may also
play roles in sex differences in CV health. Regular physical activity51-53, appropriate quantity of
sleep54-56, and dietary intake of certain foods57-60 may increase endothelial function or prevent/combat endothelial dysfunction. In parallel, stress can induce endothelial dysfunction61, as
psychosocial stress is linked to increased cortisol and inflammation (i.e., C-reactive protein,
CRP)62-65, which is a precursor to oxidative stress. Compared with men, women are less likely to
meet recommended guidelines for physical activity3 and more likely to report worse sleep outcomes and greater stress3, 66, 67. However, women are more likely to consume diets that are higher
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in plant-derived antioxidants68, and there may be important sex-specific influences of diet on endothelial function69. The potential impact of lifestyle behaviors, such as these, on endothelial
function in premenopausal women has yet to be elucidated.
Acute circulating concentrations of sex hormones in women may influence vascular or
endothelial function. In agreement with this, scientists have previously proposed that sex hormone fluctuations contribute to greater rates of vascular dysfunction in women compared with
men across the lifespan31. However, the mechanistic underpinnings between 1) NC women and
women using OCP and 2) low and high hormone phases of OCP use remain unclear. Further, the
influence of potential mediating factors, such as lifestyle behaviors, also remains unclear. Overall, these variables may contribute to the unique pathogenesis of CV conditions in women over
the lifespan.
The Microvasculature and Microvascular Function
The vasculature is the main link between the heart and any tissue in the human body. The
microvasculature, specifically, is the site of all nutrient exchange between the blood and any
given tissue. The microvascular network includes resistance arteries (i.e., arterioles), capillaries,
and post-capillary venules. Arterioles regulate total peripheral resistance, as well as tissue and
organ perfusion. Arteriolar composition is high in smooth muscle, allowing dynamic and precise
control over tissue perfusion via dilation and constriction in response to sympathetic nervous
de/activation, agonists, and/or shear stress (i.e., the frictional force of laminar blood flow over
the endothelial surface). Tissue perfusion and nutrient exchange then occurs at the capillary-tissue interface. Capillaries are composed of a monolayer of endothelial cells, allowing easy gas,
metabolite, and nutrient diffusion between blood and tissue. Blood then flows into venules,
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where some proportion of post-capillary nutrient exchange can still occur, but otherwise begins
the journey back to the right side of the heart70.
Several microcirculatory beds within the human body have been shown to provide valuable information about disease pathogenesis or progression, including the coronary71, cerebral72,
renal73, retinal74, and cutaneous2, 75 microcirculations. Microvascular dysfunction is now considered a crucial and initial pathway of CVD pathogenesis74, 76, 77 and is associated with CV mortality78, 79. Measurable microvascular dysfunction often precedes macrovascular dysfunction22-25
and can be used as an indicator of disease development or progression. Microvascular dysfunction also has prognostic value, evidenced by association between peripheral microvascular function and risk of major cardiac events in patients with stable coronary artery disease (CAD)80. For
every one standard deviation decrement in measured microvascular function (via reactive hyperemia index), there was a 40% increase in acute coronary syndrome or MI in stable CAD patients80. Therefore, the microvasculature represents a sensitive vascular bed to assess functional
changes.
Clinical Relevance of Endothelial Function
The endothelium is an essential component of vascular function. The endothelium continuously lines the vascular tree, is the interface between the blood and vessel wall, interacts directly with underlying vascular smooth muscle cells (VSMC), and is now considered a dynamic
organ81. Endothelial cells respond to and release several vasoactive substances, including NO,
COX-derived prostanoids, and EDHFs70. Endothelial cells and endothelium-dependent pathways
also respond to hormones and various neurotransmitters70. Through the response to and production of these substances, the endothelium regulates vascular tone, vasomotion, thrombosis, inflammation, and other local and systemic processes70.
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Endothelial dysfunction is a main contributing factor to chronic disease pathogenesis, including CVD82. Indeed, endothelial dysfunction is one of the earliest discernable alterations in
CVD pathogenesis70, 83. Among women, the presence of coronary or peripheral endothelial dysfunction indicates nearly 11.1- and 10.0-fold RR of major cardiac event, respectively31. Impairment of one of the primary endothelium-dependent pathways, the NO pathway, is a consistent
feature in CVD84. Therefore, individually and collectively, microvascular function, endothelial
function, and NO bioavailability represent clinically relevant components of CV health.
Endothelium-Dependent Vasodilation
This section will first review 1) the general premise of endothelium-dependent vasodilation (and constriction). This section will then discuss three endothelium-dependent pathways of
vasodilation including, the 2) NO, 3) COX, and 4) EDHF pathways. Lastly, a sub-section is included regarding 5) the interaction of these three pathways. A schematic figure of these mechanistic pathways is shown at the end of this section (Figure R1, page 20).
Endothelium-Dependent Vasodilation. In order to discuss endothelium-dependent vasodilation, we will first briefly review VSMC contraction and relaxation85. Vascular smooth muscle
cell contraction begins with an influx of calcium ions (Ca2+) into the cell, which depolarizes the
cell and triggers Ca2+ release from the sarcoplasmic reticulum through ryanodine receptors into
the cytoplasm. The Ca2+ can then bind with the protein calmodulin, creating a Ca2+-calmodulin
complex, which activates myosin light chain kinase (MLCK). Myosin light chain kinase then
phosphorylates myosin light chain (MLC), in an adenosine triphosphate (ATP)-dependent manner. Once phosphorylated, myosin can interact with actin, form cross-bridges, and yield myocyte
contraction.
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For VSMC relaxation to occur, initial depolarization must be inhibited, or the cell can be
hyperpolarized, meaning the cell membrane potential becomes more negative85, 86. Several mechanisms can inhibit MLCK phosphorylation of MLC, including two second messengers within the
vascular system, cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate
(cAMP)85, 86. Endothelial-derived molecules can also mediate the influx or efflux of ions from
VSMC, such as NO, prostacyclin (PGI2), and thromboxane (TXA2)85, 86. Further, ion channels
can be activated to impact ion influx/efflux, such as Ca2+-dependent potassium (KCa) channels85,
86

. Therefore, the endothelium can mediate VSMC relaxation and contraction, and thus, vessel

dilation and constriction, respectively. The below sub-sections discuss endothelium-dependent
pathways of vasodilation in more detail.
Nitric Oxide Pathway. Nitric oxide is a major signaling molecule within the human cardiovascular system. Nitric oxide is produced through NO synthase (NOS). There are three main
NOS isoforms, including endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible NOS
(iNOS). Nitric oxide is constitutively produced through eNOS and nNOS, and NO production
through these isoforms yields cardio- and vasculo-protective effects, such as vasodilation and
anti-thrombotic, anti-atherosclerotic, and anti-inflammatory effects23, 87. Conversely, iNOS is activated by inflammation or other damaging stimuli that induce macrophage infiltration70. Once
activated, iNOS overproduces NO, leaving NO susceptible for combination with reactive oxygen
or nitrogen species (ROS and RNS, respectively), resulting in detrimental effects, such as oxidative stress88. Endothelial NOS is found mostly on endothelial cells and is stimulated by agonists,
such as acetylcholine (ACh), bradykinin, histamine, norepinephrine, ATP, adenosine
diphosphate, substance P, and thrombin87, 89. These agonists increase Ca2+ influx into endothelial
cells. Intracellular Ca2+ then causes a confirmational change in the protein calmodulin, which
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then binds to and activates eNOS90. Activated eNOS converts the substrate L-arginine with
cofactors, such as tetrahydrobiopterin (BH4) and molecular oxygen, into NO and L-citrulline87, 91.
Nitric oxide can then diffuse across the subendothelial space to directly interact with adjacent
VSMC.
In VSMC, NO activates guanylate cyclase (GC)92 to convert guanosine triphosphate
(GTP) to cGMP87, 93. Cyclic GMP reduces intracellular Ca2+94, 95, which leads to relaxation of
VSMC and dilation of the vessel. The NO-GC-cGMP pathway then forms a positive feedback
loop, where eNOS can regulate and maintain NO production via phosphorylation by cGMPdependent protein kinases (PKGs), including protein kinase A (PKA)96, protein kinase B (Akt)97,
and cGMP protein kinase-dependent II (PKGII)98. However, NO may also be able to yield
vasodilation in a cGMP-independent manner, by directly activating KCa channels86, 99, which
allow potassium ion (K+) efflux from and hyperpolarization of VSMC.
Cyclooxygenase Pathway. The COX pathway, is an alternate endothelium-dependent
pathway that can lead to vasodilation. The COX enzymes are responsible for the synthesis of
several substances, of which some have vasoactive properties, collectively termed prostanoids.
Similar to NOS, there is a constitutive isoform, COX1, and an isoform inducible by inflammatory stimuli, COX270.
The COX pathway can also be referred to as the prostaglandin H synthase (PGHS) pathway because it first synthesizes prostaglandin H2 (PGH2) via two components: a COX component and a peroxidase component100. This pathway begins with phospholipase A2 cleaving phospholipids from the cell membrane. Phospholipids are metabolized to arachidonic acid (AA). The
COX component of the pathway adds two oxygen molecules to AA, yielding prostaglandin G2
(PGG2), and the peroxidase component then catalyzes a two electron reduction to yield PGH2100.
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Prostaglandin H2 is an intermediate prostanoid (i.e., an endoperoxide) that can be further
converted to other biologically active prostanoids via subsequent synthases, including prostacyclin (PGI2) and thromboxane (TXA2)100. Prostacyclin is synthesized by prostacyclin synthase and
binds to the prostacyclin receptor (IP receptor)101 on endothelial cells and VSMC102, through
which it elicits vasodilator and anti-thrombotic effects. Prostacyclin receptors activate adenylate
cyclase (AC), which induces cAMP synthesis. Cyclic AMP then activates protein kinase A103, 104,
yielding relaxation of VSMC and dilation of the vessel, similar to the NO pathway. However,
PGI2 may also yield vasodilation in a cAMP-independent manner, by directly activating KCa
channels105, 106. Meanwhile, inflammation and localized injury stimulate TXA2 synthesis107.
Thromboxane A2 is synthesized by thromboxane synthase and binds to the thromboxane receptor
(TP receptor)101 on platelets, immune cells, endothelial cells, and VSMCs, through which it elicits vasoconstrictor and pro-thrombotic effects. Thromboxane receptor activation, such as through
binding of TXA2, causes a Ca2+ influx into and contraction of cells, such as VSMCs, thus yielding vasoconstriction108. Prostaglandin H2 has vasoconstrictive properties itself, likely largely attributable to the fact that it also binds to and activates the TP receptor on VSMCs101.
Endothelial-Derived Hyperpolarizing Factor Pathways. Endothelial-derived hyperpolarizing factors encompass a third class of substances that, via endothelium-dependent mechanisms,
hyperpolarize VSMC. When NO and PGI2 are inhibited, VSMC hyperpolarization still occurs109,
thus leading to the discovery of EDHFs. Within the class of EDHFs, there are several contributing mechanisms or pathways, though the movement of K+ appears to play a consistent role. As
such, a consistent characteristic of EDHF is VSMC hyperpolarization resulting from the opening
of KCa channels110-112. Activation of endothelial receptors can lead to changes in Ca2+ influx and
K+ efflux from endothelial cells113. Greater subendothelial K+ concentration leads to greater K+
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efflux from VSMC, thus a more negative membrane potential, hyperpolarization, and relaxation
of VSMC113.
Epoxyeicosatrienoic acids (EET) are other AA metabolites, via conversion from cytochrome P450 epoxygenase (CP450), that is generated in endothelial cells113. Epoxyeicosatrienoic
acids also act to increase K+ efflux from VSMC, thus hyperpolarization and relaxation of
VSMC113. Epoxyeicosatrienoic acids can also directly hyperpolarize endothelial cells, which can
facilitate VSMC hyperpolarization via gap junctions113. Hydrogen peroxide is another potential
EDHF113, 114, and it is generated by several endothelial enzymes, including eNOS and COX113.
Hydrogen peroxide can also cause endothelium-dependent vasodilation, though this appears to
vary by type of vessel and species, as a result of VSMC hyperpolarization via KCa channel opening115.
Interaction of Endothelial Pathways. Endothelium-dependent pathways, including the
NO, COX, and EDHF pathways, interact with one another.
There is vast support for cross talk between the COX and NO pathways. When NOS is
inhibited in coronary arteries, PGI2 synthesis increases to maintain dilation116. Further, data from
passive-whole body heating studies suggests full elicitation of cutaneous vasodilation is dependent on regulation from both COX and NO117, 118. However, studies in aged and hypertensive
adults show increases in endothelium-dependent vasodilation with COX inhibition, where this
increase in vasodilation is concurrent with increased NO bioavailability119-122. This suggests a
potential negative impact of the COX pathway on NO bioavailability in certain populations and a
synergistic relationship of the pathways in other populations or conditions. The ratio of COXderived vasodilator and vasoconstrictor prostanoids (i.e., PGI2 and TXA2, respectively) likely
contributes to the physiological effect of COX in the vasculature.
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In populations where NO-dependent dilation is reduced, such as in African American or
non-Hispanic Black adults123, EDHF-dependent dilation appears to remain intact or is upregulated. Similarly, H2O2 has been implicated as a contributor to agonist-induced vasodilation in
disease states124, where NO is typically reduced. Further, in studies with middle-aged adults,
COX inhibition can result in increased NO bioavailability and subsequent increases in vasodilation; however, in advanced-age adults, COX inhibition leads to an increase in vasodilation that is
independent of NO, suggesting the increase in dilation may be dependent on EDHFs125. Thus,
EDHFs appear to act primarily as a compensatory pathway to maintain vasodilator capacity in
conditions where the primary vasodilator, NO, is less or not present.

Figure R1. Simplified mechanistic schematic of endothelium-dependent pathways. EDHF, endothelial-derived hyperpolarizing factor. Ca2+, calcium ions. CP450, cytochrome P450 epoxygenase. AA, arachidonic acid. EET, epoxyeicosatrienoic
acids. KCa, calcium-dependent potassium channel. H2O2, hydrogen peroxide. K+, potassium ions. NO, nitric oxide. BH4,
tetrahydrobiopterin. eNOS, endothelial nitric oxide synthase. GC, guanylate cyclase. cGMP, cyclic guanosine monophosphate. COX, cyclooxygenase. PGI2, prostacyclin. IP, prostacyclin receptor. AC, adenylate cyclase. cAMP, cyclic adenosine
monophosphate. TXA2, thromboxane. TP, thromboxane receptor.
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Cutaneous Microvascular Endothelial Function
The cutaneous microcirculation has become a valuable microcirculatory bed through
which to evaluate microvascular and endothelial function. Cutaneous microvascular function is a
model for generalized microvascular function2, 75, mimicking that of other microvascular beds,
such as the renal126, 127 and coronary128-131 microcirculations. Therefore, alterations in cutaneous
microvascular function may act as an estimate of systemic microvascular function. Cutaneous
microvascular vasodilation is largely dependent on the endothelium and endothelial-derived substances, including NO132-136. While functional assessment of other microcirculatory beds generally requires more invasive techniques to assess reliably, the cutaneous microvasculature is easily accessible and allows for reproducible in vivo mechanistic investigation. As such, study of cutaneous microvascular responses can inform current questions about vascular physiology in
premenopausal women. Below, there are sub-sections reviewing 1) techniques of assessment, 2)
the NO contribution to thermal hyperemia (defined below), 3) the COX contribution to thermal
hyperemia, 4) the EDHF contribution to thermal hyperemia, and 5) other techniques to assess cutaneous microvascular function.
Techniques of Assessment. Rapid local heating of the skin is a common technique to elicit
and assess cutaneous microvascular vasodilation135, 137, 138; this vasodilation response is termed
thermal hyperemia. Thermal hyperemia is characterized by two distinct phases of vasodilation.
First, there is an initial increase in skin blood flow (i.e., the initial peak), which is followed by a
brief fall in blood flow (i.e., the nadir). The initial peak is primarily mediated by axon reflex of
the local cutaneous sensory nerves135, 139, though EDHFs are also known to contribute to this portion of the response136, 140. This is followed by a secondary sustained plateau in blood flow (i.e.,
the plateau). The plateau is roughly 50-80% dependent on endothelial NO132, 134-136, 141. As such,
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thermal hyperemia represents one of the largest endothelial NO-dependent responses in the human body. A representative image of the thermal hyperemia response is displayed in Figure R2
(page 23).
In conjunction with rapid local heating, pharmacological techniques are commonly used
to add or inhibit vasoactive molecules or alter receptor recognition of vasoactive molecules. This
allows dissection of the pathways underlying vasodilation/constriction. Examples of these
techniques include intradermal microdialysis, iontophoresis, and intra-arterial infusion. The
strengths and limitations of these techniques have been reviewed elsewhere138. Cutaneous
iontophoresis of ACh, an endothelium-specific vasodilator, has been used in some of the key
literature to date; however, the electrical current used with iontophoresis can result in nonspecific vasodilation142. Further, iontophoresis of ACh has a limited NO-dependent
component143, and thus, may not be the most appropriate method to assess the role of the NO
pathway in vasodilation.
Nitric Oxide Contribution to Thermal Hyperemia. In 1999, Kellogg et al. delivered the
non-specific NOS inhibitor, L-NAME, to non-heated and locally heated areas of skin144. This
study established that NO is a major contributor to the dilation response to rapid local heating144.
The authors further determined that NO contributes to basal dilator tone within the cutaneous microvasculature and is required for full activation of the vasodilator system in humans144. Studies
in 2008 and 2009 implicated eNOS as the primary NOS isoform responsible for the production
of NO during thermal hyperemia132, 141.
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Nitric oxide-dependent vasodilation can be directly quantified by infusing L-NAME during the plateau phase of thermal hyperemia135. At this time, despite the constant application of
heat (at 39°C), skin blood flow will drop and come to a new plateau within ~30 minutes, termed
the post-L-NAME plateau. The quantification of NO-dependent vasodilation, including LNAME infusion and post-L-NAME plateau, are also displayed in Figure R2 (below). Several
studies replicate the NO-dependent component of thermal hyperemia at between 50-80% in
young, healthy cohorts136, 144, 145, though NO-dependent vasodilation can vary based on the rate
of heating136. When NOS is inhibited prior to local heating, the plateau achieved is substantially
reduced compared to a control plateau; however, this plateau has a greater magnitude than the
post-L-NAME plateau135. This indicates that a certain level of NO must be initially present for
full activation of the vasodilator system.
Figure R2. Example of the thermal hyperemia response, including begin heating, initial peak, plateau, begin LNAME infusion, post-L-NAME plateau, and quantification of NO-dependent vasodilation. CVC, cutaneous vascular conductance. L-NAME, N-nitro-L-arginine methyl ester. NO, nitric oxide.
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Cyclooxygenase Contribution to Thermal Hyperemia. Two methods of COX inhibition
have been most widely used within the cutaneous microvascular literature, including oral administration of aspirin and local administration of ketorolac, a non-selective COX inhibitor, via intradermal microdialysis. Notably, oral aspirin may primarily impact PGI2 generation via
COX1146 and ketorolac purportedly inhibits prostaglandin generation by both COX1 and COX2
isoforms117.
Prostaglandins do not appear to directly contribute to thermal hyperemia in cohorts of
healthy, young men117, 147. Golay et al. found that COX inhibition via oral aspirin had no effect
on thermal hyperemia in 5 young men147. McCord et al. found no COX contribution to baseline
blood flow, the initial peak, or the plateau of the thermal hyperemia response in a sample of 4
young men117. Collectively, these data suggest prostaglandins derived from neither COX1 nor
COX2 impact thermal hyperemia in young, healthy men; however, these data supply little to no
context of the possible impact within other subgroups of the population, including women. Further, these studies do not inform how COX inhibition may affect NO bioavailability during thermal hyperemia in populations with sub-optimal endothelial health or function.
Endothelial-Derived Hyperpolarizing Factor Contribution to Thermal Hyperemia. Endothelial-derived hyperpolarizing factors are independently responsible for approximately 25-50%
of the initial peak and 15-30% of the plateau in young, healthy mixed-sex cohorts (both studies
included 5 men and 5 women tested during low hormone phases of the natural menstrual cycle or
OCP use)136, 140. However, during combined NOS inhibition and EDHF inhibition, the thermal
hyperemia response is effectively abolished136, 140, indicating that during times of decreased NO
bioavailability, EDHFs may compensate to sustain dilation. Approximately, 10% of the thermal

25
hyperemia response may be attributable to EETs specifically140, leaving another EDHF responsible of the other ~5-20% of EDHF-dependent vasodilation during the plateau.
Other Methods of Assessment. There are other methods that can be used to assess
cutaneous microvascular vasodilation, including whole-body heating (either passive or active).
Whole-body heating elicits active cutaneous vasodilation, a thermoregulatory response resulting
from an increase in core body temperature148. This elicits an integrated, complex vasodilation
response that relies on a variety of mechanistic pathways148-153, some of which differ from that of
thermal hyperemia. Namely, the majority of thermal hyperemia is dependent on NO and is
mediated primarily by eNOS132, 141. Active cutaneous vasodilation is approximately 30-40%
dependent on NO154-156, and the NO component of active whole-body heating (such as via
exercise) is primarily mediated by eNOS157, 158, while passive whole-body heating is largely
regulated by nNOS133, 141, 157. Whole-body heating studies provide physiologically relevant
assessments of thermoregulatory responsiveness of the cutaneous microvasculature, but they
may not provide the same clinical relevance as assessment of the thermal hyperemia response
supported within the literature2, in part because these methods are less (or not) dependent on
endothelial NO.
Four studies investigating the impact of COX inhibition on active cutaneous vasodilation
(via passive whole-body heating) provide perspective regarding the possible impact of vasoconstrictive prostanoids (e.g., TXA2 or PGH2) on basal blood flow and NO bioavailability within the
cutaneous microvasculature. Healthy, middle-aged, chronic oral aspirin users (3 men, 4 women;
57 ± 3 y) show no difference in baseline blood flow from healthy, middle-aged controls (4 men,
3 women; 55 ± 3 y)118. Further, young, healthy mixed-sex cohorts (4 men, 4 women in the low
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hormone phase of OCP use117; 7 men, 5 women in the EF phase of the natural menstrual cycle125) show no difference in baseline blood flow between control and ketorolac-infused intradermal microdialysis sites. However, in mixed-sex cohorts of middle-age (6 men, 7 women; 53 ± 2
y)119 and advanced-age (5 men, 5 women; 69 ± 1 y)125 adults, local infusion of ketorolac increases baseline blood flow compared with that of control sites, suggesting the basal presence of
vasoconstrictive prostanoids. Further, baseline blood flow can be reduced during co-infusion of
ketorolac and L-NAME119, suggesting acute COX inhibition with ketorolac can increase NO bioavailability in humans that may have a shift towards greater basal presence of vasoconstrictive
prostanoids.
Hormonal Profiles of Premenopausal Women
As noted above, women experience complex hormonal changes across the lifespan but
also distinctly during premenopausal years in a monthly cycle. This includes several endogenous
hormones that fluctuate across the natural menstrual cycle and possible exposure to sources of
exogenous hormones via hormonal methods of contraception. Oral contraceptive pills are the
most common hormonal contraception method in the United States159 and are, thus, an important
factor to consider in vascular health in premenopausal women. Below are descriptions of the
basic hormonal profiles of premenopausal women 1) across the natural menstrual cycle or 2) during OCP use.
Natural Menstrual Cycle. Across the natural menstrual cycle, endogenous hormones fluctuate in a cyclic pattern every 25 to 33 days on average (median, 28 days)160. This includes estrogens (namely estradiol), progesterone, luteinizing hormone, follicle stimulating hormone (FSH),
testosterone, and others. The natural menstrual cycle is controlled by the hypothalamic-pituitaryovarian (HPO) axis85. The hypothalamus secretes gonadotropin releasing hormone (GnRH),
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which stimulates the anterior pituitary to release FSH and luteinizing hormone85. Follicle stimulating hormone enables follicle development and maturation and stimulates the release of estrogens from the maturing follicles85. Luteinizing hormone allows ovulation to occur (i.e., the release of an egg from an ovary) and stimulates the formation of a corpus luteum following ovulation, which secretes estrogens and progesterone85. For this review and dissertation, we will focus
on the effect of the two primary sex hormones in women, estradiol and progesterone.
The natural menstrual cycle can be separated into distinct phases based on endogenous
hormone production. These phases will be referenced hereafter as M/EF, late follicular (LF), ovulatory (OV), early luteal (EL), mid-luteal (ML), and late luteal (LL). Sample estradiol and progesterone production rates are provided for each phase below. During M/EF, the production of
estradiol (36 µg/day161) and progesterone (1 mg/day161) are low respective to the following
phases. During LF, estradiol rises to peak production (380 µg/day161) around d 11-19 (depending
on cycle length)160, and progesterone production remains low (4 mg/day161). The estradiol peak
occurs, and OV follows, corresponding with a relative fall in estradiol concentration, though still
elevated, and a peak in luteinizing hormone and FSH. The EL phase is characterized by elevated
estradiol and rising progesterone, where neither are at peak production rates. Finally, ML to LL
is characterized by still sustained elevation in estradiol (estradiol: 250 µg/day161) and peak progesterone (25 mg/day161). An example of endogenous estradiol and progesterone production in
time across a 28-day cycle is displayed in Figure R3 (following page).
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Oral Contraceptive Pills. As mentioned, OCP are one of the most common contraception
methods overall for premenopausal women and the most common hormonal method. In 2019,
approximately 151 million women were using OCP worldwide162. In recent surveys from the
United States and Canada, approximately 14-16% of premenopausal women currently use
OCP159, 163. The potential impact of OCP on premenopausal women becomes more apparent
when considering lifetime use. Between 2006 and 2010, 82% of premenopausal women in the
United States had ever used OCP164. Though current estimates of lifetime OCP use are lacking,
similar estimates of lifetime use have been indicated in other countries, such as Australia
(75%)165 and Sweden (80%)166.
The mechanism of action of OCP is through the interruption of the HPO axis. During
OCP use, there are consistent hormone levels (EE and progestin) throughout the high hormone
phase, when active pills are being taken167. The progestin component, through negative feedback,
prevents the hypothalamus from secreting GnRH167. Without the secretion of GnRH, there is no
release of luteinizing hormone or FSH, and thus, no follicle development or ovulation. Because

29
of this, there is no natural production of estrogens or progesterone. Then, because of the withdrawal of exogenous hormones during the low hormone phase of OCP use (i.e., the placebo
pill/pill-free week), a withdrawal bleed occurs, which has no physiological relevance167.
Combination OCPs are formulated with a variety of pharmacological agents and dosages.
Combination OCP are the most commonly used form and are those that include both a synthetic
form of estrogen and progestin163. EE is the synthetic estrogen component in nearly all modern
combination OCP formulations163. Current formulations typically include a low dose of EE,
ranging from 20-35 g168, though there are still formulations used that include up to 50 g. Synthetic progestins are generally classified into four generations and vary in potency, androgenicity, and side effects168-170. First generation progestins (e.g., norethindrone, norethindrone acetate,
and ethynodiol) are estranes and are derived from 19-nortestosterone. Second generation progestins (e.g., levonorgestrel and norgestimate) are gonanes and have a greater androgenicity than estranes. Third generation progestins (e.g., desogestrel and gestodene) are also gonanes, but they
have reduced androgenicity and metabolic effects compared with second generation progestins,
likely because they must be metabolized before becoming bioactive. Fourth generation progestins (e.g., drospirenone and cyproterone acetate) are derived from spironolactone and have
greater anti-androgenic and anti-mineralocorticoid properties than earlier progestins.
Combination OCP also vary in regimen as monophasic, biphasic, or triphasic, in which
the dosage of EE or the included progestin may be consistent or change across pills for the
month168. Monthly regimens typically include pills for 28 days, including 21 or 24 active pills
and 7 or 4 placebo or sham pills, respectively, though extended cycle formulations also exist168.
An example of circulating concentration of EE and progestin across a cycle of monophasic, combination OCP is displayed in Figure R4 (following page). At present, hormonal OCP remains a
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complex variable contributing to vascular physiology in premenopausal women, and there are
many facets of which have not been studied to date7.

Premenopausal Hormonal Profiles and Experimental Testing
Premenopausal women are often restricted to experimental testing during low hormone
phases, such as the M/EF phase (~d 1–7) of the natural menstrual cycle or placebo pill phase of
OCP use. This is based in minimizing the effect of estrogen on experimental outcomes, seeing
that men do not share a similar rise in estrogen concentrations. However, the influence of circulating testosterone concentrations when testing young men in similar types of research is considered far less often. Further, women in respective low hormone phases are often grouped together
as a seemingly homogenous group, including in the field of cutaneous microvascular research.
However, objective support of this notion remains uncertain. Additionally, findings regarding endothelial function between low and high hormone phases of OCP use remain inconsistent.
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Criteria to determine experimental time frames for phasic testing are inconsistent within
the relevant literature. In 2018, a publication proposed specific dates within a monthly cycle to
test premenopausal women during either the natural menstrual cycle or during monophasic OCP
use in order to reduce the ambiguity of scientific experimental design for comparing differences
in sex, NC phase, or endogenous/exogenous hormone exposure170. When comparing low hormone phases in NC women and women using OCP, matched experimental testing should occur
on d 2-5 of the natural menstrual cycle (M/EF phase) and d 1-2 of placebo pills during OCP
use170. During OCP use, peak circulating EE and progestin concentrations are typically reached
within 1-2 hr of oral consumption, with molecules clearing the system within 10-24 hr on average171. Elevations in endogenous estradiol and follicular maturation have been recorded towards
the end of the placebo pill week of OCP use172, 173, indicating later days within the placebo pill
week may allow reawakening of the HPO axis, accounting for rises in endogenous hormone production within 7 days. Therefore, d 1-2 of placebo pills in the OCP monthly cycle should correspond to low circulating concentrations of exogenous EE and progestin, as well as endogenous
estradiol and progesterone. Further, d 3-6+ of active pills is suggested as the high hormone
match during OCP use170. Relevant phasic comparisons for premenopausal women in differing
hormonal states (i.e., NC and using OCP)170 that are used in this dissertation are summarized in
Table R1.
Table R1. Relevant Phasic Comparisons
Across or Within Hormonal State
NC Women
Women Using OCP

Low
Hormone
d 2-5 of M/EF

High
Hormone
---

d 1-2 of placebo pills

d 3-6+ of active pills
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Sex Hormones and Endothelial Function
Sex hormones can modulate endothelial function. The below sub-sections will discuss
how endothelial function is influenced by 1) endogenous estradiol and progesterone, 2) exogenous EE and progestins, and 3) testosterone.
Endogenous Estradiol and Progesterone. Endogenous estradiol improves, or maintains
healthy, endothelial function. Estrogen receptors (ER) are present on both endothelial cells and
VSMC174-178. Estradiol binding to ERs causes a subsequent increase in NO production and/or bioavailability174, 179-181. Estradiol modulates NO production by increasing eNOS activity182-184 in
an ER-dependent manner185. Estradiol increases ER expression, such that ERα (a subtype of ER)
expression is approximately 30% higher in menstrual cycle phases with elevated estradiol186,
suggesting an acute impact of estradiol concentration on ER expression. The quantity of ERα is
further correlated with eNOS expression and phosphorylation186. In parallel, plasma nitrite and
nitrate, an estimate of NO production, is highest during the LF phase187, coinciding with peak
plasma estradiol concentration. Therefore, there is a consistent link between endogenous estradiol, ER expression, eNOS expression and activity, and thus, healthy endothelial function.
In vitro data similarly support this relationship. Estradiol concentrations similar to circulating levels during the EF phase of the natural menstrual cycle (100 pg/mL188) do not increase
NO production in human endothelial cells. However, concentrations that mimic circulating estradiol during mid to LF and OV phases (300 and 600 pg/mL188, respectively) do increase NO production9. The upregulation in NO production at these concentrations of estradiol is, again, ERand NOS-dependent.
In vivo studies further support this effect of estradiol on endothelial function. This has
been shown between various subgroups of the populations. In vivo endothelial function decreases
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through natural hormonal phases in women across the lifespan, such that endothelial function decreases stepwise through premenopausal women, women in early then late peri-menopause, followed by women in early then late postmenopause189. Additionally, men administered an aromatase (i.e., the enzyme that converts testosterone into estrogen) inhibitor display significantly decreased in vivo endothelial function compared with controls190. Further, estradiol also acts to decrease concentrations of endothelin-1 (ET-1)191-193, a potent vasoconstrictor that is typically inversely related to NO bioavailability and NOS expression194-198. As such, a decrease in ET-1
could result in a greater NO to ET-1 ratio, and thus, a physiologic preference towards dilation
versus constriction. The cardio- and vasculo-protective qualities of estradiol are likely linked to
its effects on bioavailable NO.
The in vivo effect of endogenous progesterone on endothelial function is less clear. Progesterone may exert positive effects on vascular and endothelial function. In rat aortic rings, progesterone can stimulate NO and PGI2 release199. Further, in human endothelial cells and rats,
progesterone increases eNOS expression in a progesterone receptor-dependent manner200. This
translates to functional parameters, as progesterone receptor inhibition reduces arterial vasodilation in rats200. However, in cultured VSMCs and vessels from ovariectomized mice, progesterone
antagonizes positive estradiol effects201. The direct impact of endogenous progesterone on endothelial function in humans remains unclear, in part because endogenous progesterone only increases in conjunction with endogenous estradiol during the natural menstrual cycle. As such,
estradiol is typically considered the primary sex hormone contributing to cardio- and vasculoprotection in women during premenopausal years.
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Ethinyl Estradiol and Synthetic Progestins. The effects of exogenous sex hormones appear to vary based on whether they are administered in a premenopausal (i.e., OCP) or postmenopausal (i.e., hormone replacement therapy) state. For the purposes of this dissertation, discussion will focus on the effects during OCP use in premenopausal women.
Ethinyl estradiol may affect the endothelium differently than endogenous estradiol. Various EE concentrations in vitro, including those that mimic minimum and maximum circulating
EE concentration within 24 hr of oral administration (20 pg/mL and 150 pg/mL EE171, respectively), do not increase NO production in human9 or bovine8 endothelial cells. Further, EE does
not affect NOS expression (NOS protein content or NOS mRNA)8. Indeed, 7 days of EE exposure (0.05 mg) in initially OCP-naïve, premenopausal women does not increase in vivo NO production191. However, 7 days of EE administration did result in a decrease in ET-1, which again,
could result in a greater NO to ET-1 ratio and a positive physiologic outcome191. EE may also
increase basal endothelial cell NO release, though this appears to be due to reductions in ROS
generation and not increases in NO synthesis8.
Combination OCP use also does not appear to impact NO production in the same manner
as endogenous hormones. Three months of second generation OCP use decreases202 or does not
impact NO production203. Similarly, third generation OCP use does not affect NO production203.
Further, neither second nor third generation use impacts ET-1 or the NO to ET-1 ratio203. This
might suggest an antagonistic effect of progestins, considering previous literature addressing EEonly exposure on ET-1191. One study in humans reported increased eNOS mRNA in skin punch
biopsies from OCP users compared with NC women204, though NC women in this study were
tested during the M/EF phase, during which ERα and eNOS expression have been shown to be
acutely reduced186. However, regardless of this increase in eNOS expression, OCP users in this
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study displayed blunted vascular responses to L-arginine infusion204, suggesting lesser NO synthesis or lesser ability of NO to exert a vasodilator effect.
Other factors affect endothelial function, such as asymmetric dimethylarginine (ADMA,
an endogenous eNOS inhibitor), L-arginine availability, and CRP. One study assessed these factors in a cohort of women, including 318 women using OCPs and 761 women not using OCPs205.
Included women were using OCPs of varying EE doses, progestin doses, and progestin generations, as well as progestin-only and multi-phasic formulations. Therefore, conclusions from this
should be made carefully. Women using OCP in this cohort had decreased ADMA and increased
L-arginine levels compared with NC women. This would translate to an increased L-arginine to
ADMA ratio, which would also favor dilation versus constriction. However, despite what would
appear to positively influence endothelium-dependent vasodilation from a molecular standpoint,
measured endothelial function was similar between OCP users and NC women in this study. This
could suggest an increase of NO pathway activity in OCP users but decrements in other endothelium-dependent pathways or other unfavorable molecular constraints. However, when data from
this study is further assessed, women using progestin-only formulations had significantly higher
ADMA levels, but 2-3-fold lower CRP levels and greater endothelium-dependent vasodilation,
than women using combination (EE + progestin) formulations. This further suggests an impactful role of CRP on endothelial function in combination OCP users.
Testosterone. Currently, the effect of testosterone on endothelial function is not fully elucidated in either men or women. Physiological levels of testosterone reduce atherosclerotic risk
in men206, 207, suggesting beneficial effects of testosterone on the vasculature and endothelium.
Indeed, lower serum total and free testosterone is associated with decreased endothelial function
in men208. Testosterone increases endothelium-dependent vasodilation in male animal models,
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mediated in part by NO209, 210. Testosterone may also impact opening of K+ channels though, and
thus, may impact EDHF-mediated mechanisms211. Further, testosterone is the main source of estrogen in men, via conversion by aromatase212. As such, testosterone mediates estrogen actions in
men and may impact endothelial function in this way. However, testosterone administration can
reduce endothelium-dependent vasodilation and NO bioavailability in other subgroups of men or
male animals213, 214. In women, higher circulating testosterone levels appear harmful to endothelial function, where these women also exhibit inflammatory markers, oxidative stress, and increased ET-1, all known to impact endothelial function and NO bioavailability215-217.
Pathways Detrimental to Endothelial Function
There are several molecular mechanisms through which endothelial function can be negatively affected, including of most pertinence to this dissertation, 1) oxidative stress and 2) inflammation.
Oxidative Stress. Oxidative stress is the imbalance of ROS generation and antioxidant
defenses. Whether due to increased ROS generation or decreased antioxidant defenses, oxidative
stress plays a key role in the pathogenesis of several chronic diseases, including many CV
conditions13. This may be largely due to the impact of oxidative stress on eNOS and NO, and
thus, endothelial function.
While ROS are important regulators of signaling pathways within the human body, their
presence in excess can cause damage to cellular components218. Reactive oxygen species are
molecules that contain unpaired electrons, through which they can react with other substances.
Common ROS include hydroxyl radicals (OH), superoxide (O2-), and peroxynitrite (ONOO-)219.
Nitric oxide is also a free radical, meaning it is highly reactive and can easily combine with other
molecules, such as ROS. For instance, NO and O2- combine to form ONOO-. Normal biological

37
processes produce ROS, such as the metabolism of AA by CP450 or COX, the endothelial generation of NO by NOS, and many others220.
While free radicals and ROS can react with each other, they easily react with non-radical
substances as well, such as proteins and lipids220. Oxidative stress can act directly on the eNOS
protein, by inactivating or uncoupling eNOS. When eNOS is uncoupled, there is reduced NO
production and, instead, increased O2- production13. Endothelial NOS uncoupling can occur
through oxidative stress via depletion of the cofactor BH4 to dihydrobiopterin (BH2)221, disruption of eNOS dimerization222, induced S-glutathionylation of cysteine residues on the reductase
domain of eNOS223, 224, induced increased production/decreased degradation of ADMA225, or adverse phosphorylation of eNOS226-228. Considering phosphorylation, serine1177 phosphorylation
activates eNOS229 and leads to greater NO production. However, oxidative stress can induce
phosphorylation at tyrosine657227 or threonine495230, 231, which both lead to eNOS inactivation
and can result in eNOS uncoupling (via threonine495 alone)231. Another biological marker of oxidative stress is isoprostanes100. Isoprostanes are generated via AA peroxidation by free radicals
(i.e., independent of COX)100. Isoprostanes are structurally similar to other prostanoids, such as
PGI2 and TXA2, but also have potent vasoconstrictive actions, especially within the setting of reduced antioxidant capacity100, 232.
Antioxidants delay or inhibit the oxidation of other substances. Pertinent antioxidants include superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase219. These cellular
antioxidants break down ROS, such as O2- or hydrogen peroxide (H2O2), into less reactive products. There are several other non-enzymatic antioxidants, such as vitamin A (i.e., retinol), vitamin C (i.e., ascorbate), vitamin E (i.e., α-tocopherol), -carotene, and coenzyme Q, that collectively work to scavenge free radicals within the human body219, 220.
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Inflammation. Several markers of inflammation are independent risk factors for CVD, including CRP14. C-reactive protein activates nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase233, which increases O2- generation, and is linked to eNOS uncoupling48. Thus,
CRP contributes to reductions in NO bioavailability and increased oxidative stress. Indeed, CRP
has demonstrated negative effects on endothelial function and NO bioavailability49, 50. C-reactive
protein may also have direct effects on thrombosis, such that CRP modulates changes in the
COX pathway in a manner that favors thrombosis234, 235. Specifically, CRP suppresses prostacyclin synthase expression and augments TP receptor expression234, 235. This would result in decreased PGI2 generation and increased effects of TXA2 or other endoperoxides, respectively.
Therefore, CRP has various effects on the endothelium that may contribute to reduced vascular
or endothelial function.
Oxidative Stress and Inflammation in Naturally Cycling Women
Endogenous sex hormones can modulate oxidative stress and inflammation in premenopausal women. The below sub-sections will discuss how fluctuations in endogenous estradiol
and progesterone impact 1) oxidative stress and 2) and inflammation.
Oxidative Stress. The distinct and collective effects of endogenous estradiol and progesterone on oxidative stress are not clear. Most in vivo investigations support an antioxidant role of
estradiol236-238. There are some conflicting results237, though the majority of opposing data are in
hyperestrogenic concentrations. Physiologic concentrations of endogenous estradiol (100, 300,
and 600 pg/mL) protect endothelial cells against H2O2-induced oxidative damage in a dose-dependent manner9. However, based on the minimal in vivo data available, distinct conclusions
concerning oxidative stress across the natural menstrual cycle cannot be made. One study con-
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cluded that healthy, NC women reside in an elevated oxidant condition for two-thirds of the normal menstrual cycle239. This study presented data corresponding to an increase in plasma hydroperoxides (another marker of oxidative stress) from d 1 to d 15 of the natural menstrual cycle,
with the peak hydroperoxide value measured near peak endogenous estradiol239. Following d 15,
there was a general decline in hydroperoxide value, but oxidant status remained in the elevated
range239. Another study supports the pattern of increased oxidant status during EL, ML, and LL
phases240.
Conversely, findings support a linear relationship of both endogenous estradiol and progesterone with antioxidant status241, 242. Serum levels of retinol and α-tocopherol positively correlate with serum estradiol concentration241. Further, α-tocopherol and coenzyme Q10 are significantly lower during the follicular phase compared with the luteal phase within the same onemonth cycle242, suggesting a positive effect of progesterone. Indeed, ascorbate positively correlates with serum progesterone concentration as well241. Therefore, endogenous estradiol and progesterone may more consistently impact oxidative stress via positive impacts on antioxidant defenses than direct effects on ROS generation.
Inflammation. Again, many in vivo investigations support an anti-inflammatory role of
estradiol236, 238, 243-246, but there are some conflicting results245, 246, mostly concerning hyperestrogenic concentrations. Endogenous estradiol and progesterone may have opposing effects on inflammation. There is well-established support for an inverse relationship between endogenous
estradiol and markers of inflammation238. CRP increases ~17% during the M/EF phase of the
menstrual cycle compared with the ML phase247, 248. Indeed, a ten-fold increase in endogenous
estradiol is associated with a 24-29% reduction in CRP248, 249.
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High levels of homocysteine, another inflammatory agent, lead to endothelial damage,
and as such, homocysteine is an independent risk factor for CVD250. Data also suggest an inverse
relationship between estradiol and homocysteine, which has been shown in vivo across phases of
the natural menstrual cycle 191, 251, 252. While progesterone concentration also inversely relates to
plasma homocysteine252, progesterone concentration is linearly associated with CRP during the
normal menstrual cycle, with a ten-fold increase in endogenous progesterone concentration portraying a 19-23% increase in CRP248, 249.
Oxidative Stress and Inflammation in Women Using Oral Contraceptives
Exogenous sex hormones can also modulate oxidative stress and inflammation in
premenopausal women. The below sub-sections will discuss how OCP use impacts 1) oxidative
stress and 2) and inflammation.
Oxidative Stress. Ethinyl estradiol may have different effects on oxidative stress than endogenous estradiol. In vitro experiments with human endothelial cells indicate that EE at several
concentrations (20, 40, 125, or 150 pg/mL) does not provide protection against H2O2-induced oxidative stress9. However, EE does decrease O2- anion production in a dose-dependent manner
from 0.01 nM to 0.01 M in bovine endothelial cells8, which is concurrent with an increase in
basal NO release. Different effects of EE than endogenous estradiol have been documented in
other endothelial cell functions253. Therefore, these findings propose that EE may affect in vivo
endothelial function differently than endogenous estradiol, or they may elicit results through different molecular pathways.
Combination OCP use appears to increase ROS generation in vivo. Female rat models
suggest OCP significantly increases blood lipid peroxides254, 255. In vivo studies in premenopausal women suggest OCP use increases oxidative stress10, 256-258. Healthy, premenopausal women
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using OCP have increased levels of lipid peroxides256, 257 and oxidized low-density lipoprotein256
compared with NC women. Three months of OCP use (in previously OCP-naïve women) substantially elevates ROS production259. Data also suggest reduced vascular NO bioavailability, assessed by heme-nitrosylated hemoglobin concentration, in OCP users compared with NC
women, and this finding correlates with increased plasma peroxides, decreased erythrocyte-reduced thiols, and a trend towards endothelial dysfunction in OCP users258. In women athletes,
92.9% of those using OCP exhibit elevated oxidative stress measured by the free oxygen radical
test (assessed by the FORT assay), compared with 23.5% of NC women10. Women using OCP in
this study also displayed two-fold the measured hydroperoxides compared with NC women10.
It is unclear whether the negative oxidative effects of OCP are resultant from EE or the
included progestin components258, 259. Some data suggest the progestin component contributes to
measured oxidative stress, such that levonorgestrel, gestodene, drospirenone, and cyproterone
acetate all significantly increased oxidative stress compared with controls, while desogestrel led
to a non-statistically significant increase258. Conversely, another progestin, dydrogesterone, has a
very similar molecular structure to natural progesterone and appears to produce beneficial vascular effects with consistent use259. However, dydrogesterone is no longer available for commercial
sale in several countries (including the United States) and has very little effect on gonadotropin
(i.e., FSH or luteinizing hormone) release at clinically used dosages, therefore not interrupting
ovulation260. Thus, some negative vascular effects of combination OCP use may be directly related to interruption of the HPO axis.
Antioxidant defenses are also affected by OCP. Serum coenzyme Q10242, α-tocopherol242,
and -tocopherol257 are significantly decreased in OCP-users compared with NC women. There
is also a strong association between decreased β-carotene and OCP use257, 261-266. Women athletes
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using OCP have decreased free oxygen radical defenses (assessed by the FORD assay) compared
with NC women10. Healthy lifestyle habits (e.g., exercise and consuming an antioxidant-rich
diet), did not correlate with measured hydroperoxides in this sample of women athletes10, suggesting that concurrent practice of typically beneficial lifestyle behaviors may not be able to
counteract some detrimental consequences of OCP use. There are some contradictory studies that
show a positive effect of OCP use on antioxidant enzyme activity, such as catalase267 or glutathione peroxidase (GPx) 267, 268; however, it’s possible this increase in enzymatic antioxidants could
be a compensatory increase resulting from increased oxidative stress.
Inflammation. Women using OCP also have increased markers of inflammation11, 259, 269.
C-reactive protein is elevated in OCP users compared with NC women11, 12, 205, 269, and high-sensitivity CRP (hsCRP) increases within just three months of initial OCP use259. Women using
OCP show greater lymphocyte and lower monocyte counts compared with NC women, indicating elevated lymphocyte-to-monocyte ratio, another marker of inflammation11, 269. In a cohort of
healthy, women athletes, protective hsCRP levels (< 0.5 mg/L) were found in 17.0% of OCP users and 64.5% of NC women, and hsCRP levels indicative of CV risk (≥ 1.0 mg/L) were found
in 62.3% of OCP users and 13.2% of NC women. Further, high hsCRP levels (3.0 to < 10.0
mg/L, suggesting high risk of future CV event) were found in 26.4% of OCP users and only
2.6% of NC women (OR = 13.3)11. Interestingly, exercise negatively correlates with measured
hsCRP in NC women only11, again suggesting typically beneficial health habits may not be able
to counteract detrimental effects brought on by OCP. This suggests OCP use instigates chronic
low-grade inflammation, which may be harder to regulate with lifestyle interventions. This
places women using OCP in a vulnerable position to protect their CV health, both acutely and
long-term.
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Sex Differences in In Vivo Microvascular and Endothelial Function
This section will detail the current literature regarding sex differences in in vivo function
of 1) the cutaneous microvasculature, 2) other microvascular beds, and 3) the endothelium in
conduit vessels.
Cutaneous Microvascular Function. Two studies have directly assessed sex differences
in thermal hyperemia induced by rapid local heating to 42°C in young, healthy adults26, 270. Endothelium-dependent vasodilation is similar between men and women in the EF26, 270 or ML270
phase. All women in one study were NC26. Though hormonal exposure (NC or OCP) was not
specified in the other study, experimental testing visits were termed either EF or ML for women,
thus it is assumed women were NC270. Rapid local heating to 42°C typically elicits ~90-95%
maximal vasodilation within the skin136. This suggests that premenopausal women have similar
near maximal endothelium-dependent vasodilator capacity compared with young men, including
during the EF phase of the natural menstrual cycle when circulating estradiol is low. However,
NO-dependent dilation was lower in women in the EF phase (52 %NO) compared with men (71
%NO)26. Therefore, premenopausal women in low hormone phases may have a decreased reliance on NO to elicit dilation within the cutaneous microcirculation with this thermal stimulus.
Another study assessed sex differences in thermal hyperemia to local heating to 39°C in a
subset of Black young adults, but it is unclear if this subgroup analysis was appropriately powered27. Endothelium-dependent vasodilation was similar between men and women in this study.
This study further reported no differences in NO contribution to thermal hyperemia between men
(~25 %NO) and women (~30-35% NO). While all women were tested during low hormone
phases, both NC women and those using OCP were included, though it is not clear how many
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women under each hormone exposure were present in the sample. This data gives an initial perspective on sex differences in thermal hyperemia at 39°C; however, it is well-documented that
healthy, Black young adults display reduced magnitude of thermal hyperemia and NO contribution to local heating than White young adults271-274. From this data, it remains unclear how selfidentified race or endogenous/exogenous hormone exposure (NC or using OCP) may affect sex
differences in endothelium- and NO-dependent vasodilation at this time.
The presence of sex differences in cutaneous vasodilator responses to other methods of
assessment are inconsistent275-279. Studies assessing active cutaneous vasodilation suggest no sex
differences277-279. This includes assessments of active cutaneous vasodilation in response to passive heat stress277 or exercise heat stress278, 279. There also do not appear to be sex differences in
the mediating activity of NOS or heat shock protein 90 (via its contribution to NOS stability) in
the response278, 279. It is important to note that the women included in these studies were both NC
women and women using OCP, all tested during low hormone phases277, 279. Further, resting
hand and finger blood flow, as well as skin perfusion, are greater in men compared with
women275. However, women may have greater increases in skin blood flow in response to wholebody heating compared with men but may also display greater basal sympathetic activity regulating cutaneous blood flow275. Conversely, there are no observed sex differences in cutaneous microvascular endothelial function induced by pharmacological infusion of ACh277. All women in
this study were tested during a low hormone phase, and 4 of 12 women participants were using
unspecified OCP277. Interestingly, this finding277 simultaneously contradicted a prior hypothesis
within the literature that suggested the cutaneous microvasculature is more reactive to pharmacological stimuli in women compared with men280.
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Other Microvascular Beds. Coronary flow velocity reserve (CFVR, an indicator of coronary microvascular function) is similar between men and premenopausal women during the
M/EF phase of the natural menstrual cycle, but CFVR is elevated during the MF phase compared
with men281, corresponding with an increase in circulating estradiol. While the phase of experimental testing for women was not reported, lower limb skeletal muscle microvascular function
appears to be greater in young women compared with young men282. However, data suggest oxidative stress may play a role in lower limb microvascular dysfunction induced by prolonged sitting in young men but not in young women (low hormone phase). This indicates that mechanisms underlying microvascular dysfunction in general may be subject to sex differences.
Conduit Vessel Endothelial Function. In general, more endothelial function research has
been completed in the macrovasculature (i.e., conduit vessels) than in the microvasculature. Brachial artery endothelial function is an independent risk factor for CVD283, typically assessed via
brachial artery flow-mediated dilation (FMD), a well-established marker of conduit vessel endothelial function. Some publications suggest greater brachial artery FMD in women compared
with men284-287, while others suggest no sex differences in FMD responses288-290. Other literature
suggests FMD is comparable between men and women in the M/EF phase, when the concentration of estradiol and progesterone are most similar between sexes, but increases in women during
the LF and luteal phases291, 292. However, when scaled allometrically, one study concluded
greater FMD in men compared with NC women or women using OCP288. Further, women retain
FMD responses following ingestion of a high-fat meal, throughout M/EF, LF, and ML phases,
while FMD in men is reduced292. As such, there may be sex-specific defenses that protect NC
women from endothelial damage following acute insult, independent of acute hormonal changes.
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Summary. Most data suggest no differences in microvascular or endothelial function between men and women. However, other reports suggest microvascular or endothelial function
may be similar between men and women in low hormone phases but may increase in women
during high hormone phases, which would support a role of acute circulating hormone concentration. In the cutaneous microvasculature, NO-dependent vasodilation appears to be lower in
NC women in the M/EF phase compared with men26; however, a cohort NC and OCP-using
women showed similar NO-dependent vasodilation compared with men27. This may suggest differing NO bioavailability between NC women and women using OCP during respective low hormone phases. There is further evidence that some aspects of microvascular or endothelial function may differ between sexes, including greater sympathetic regulation in women (thus affecting
basal vascular tone), a greater influence of oxidative stress in men than women, and greater defenses against acute insult in NC women.
In Vivo Microvascular and Endothelial Function in Naturally Cycling Women
This section will review the literature regarding the natural menstrual cycle and in vivo
function of 1) the cutaneous microvasculature, 2) other microvascular beds, and 3) the endothelium in conduit vessels.
Cutaneous Microvascular Function. Studies investigating cutaneous microvascular vasodilation and endogenous hormone changes in premenopausal women have yielded inconsistent
results293-295. Four studies have directly investigated the effect of changes in endogenous female
sex hormones across the natural menstrual cycle. Thermal hyperemia (local heating to 42°C) is
similar between the ML phase (91 ± 2 %CVCmax) and EF phase (89 ± 2 %CVCmax)296. Nitric oxide contribution was not directly assessed in this study296. Three studies used cutaneous iontophoresis of ACh to assess cutaneous endothelium-dependent vasodilation, but as noted, this
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method has a limited NO-dependent component143. Two reported no variation in endotheliumdependent vasodilation across phases294, 295, and one reported increased endothelium-dependent
vasodilation in late stages of the follicular and luteal phases (LF and LL) compared with early
stages of the phases (EF and EL), respectively293.
Other Microvascular Beds. Microvascular function has been assessed in several microcirculatory beds in premenopausal NC women. Data support a linear relationship between coronary
microvascular function and estradiol concentration. In the coronary microcirculation, premenopausal women have greater CFVR during the MF phase compared with the M/EF phase281. During peri-menopause, coronary microvascular dysfunction leads to functional impairments that
coincide with decreased NO production, increased oxidative stress, and increased proinflammatory cytokine release297, thus implicating decreased estradiol in endothelial dysfunction. Further,
data from the Women’s Ischemia Syndrome Evaluation (WISE) study indicate half of women
with coronary microvascular dysfunction also have variant angina298. Taken together with data
indicating exacerbations of variant angina in premenopausal women during low hormone phases
of the natural menstrual cycle44, 45, this thereby indirectly links estradiol concentration, microvascular function, and clinically relevant depictions of cardiovascular disease in women.
Cerebrovascular reactivity (CVR) is an assessment of cerebral microvascular function299.
In premenopausal women, CVR was increased in the region of the brain supplied by the right internal carotid artery across distinct phases of the menstrual cycle299. Several methodologies can
be used to assess peripheral microvascular function, including passive leg movement or venous
occlusion plethysmography (VOP), which assess limb blood flow mediated by skeletal muscle,
the skin, and other supporting tissues. Peak and total forearm and calf blood flow, assessed by
VOP, are greatest in premenopausal women during the LF phase compared with other phases187,
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coinciding with peak estradiol concentration. However, there were no menstrual cycle phase differences in sub-groups of Black or White women in response to passive leg movement300.
Conduit Vessel Endothelial Function. Some studies, but not all288, 301, support improved
conduit vessel endothelial function during time periods of elevated estradiol45, 186, 287, 290-293, 302.
Congruently, FMD is ~30% lower in postmenopausal compared with premenopausal women186.
FMD is positively correlated with ERα expression in women of all endogenous hormone status
(i.e., pre-, peri-, or postmenopausal), and ERα expression overall increases during time periods
of elevated estrogen concentration186. This would suggest that FMD may also vary with acute
fluctuations in estradiol concentration, such as across phases of the natural menstrual cycle.
However, data describing conduit vessel endothelial function in premenopausal women across
the menstrual cycle are incongruent.
There is support for increased FMD during phases of increased estradiol concentration,
such as the LF and LL phases45, 186, 291-293, 303. Yet, other studies indicate no difference between
phases that typically have different estradiol production rates, such as between M/EF and LF
phases288, 301 or between LF and LL phases 291, 293. Further data indicate FMD may be least during the M/EF phase and greatest during the LF phase187, 288. Data also indicate lowest FMD responses immediately following OV293 (during the EL phase), which corresponds with a time period just following peak estradiol, luteinizing hormone, FSH, and testosterone concentrations and
is concurrent with rising progesterone concentrations for the first time during a monthly cycle.
Ischemia-reperfusion injury (IRI) is another technique to assess endothelial function304.
The reperfusion of blood following an ischemic period of time can instigate endothelial dysfunction in humans, as restoration of blood flow can result in inflammation and oxidative stress304.
Ischemia-reperfusion injury as a research methodology mimics pathological IRI conditions; for
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instance, significant atherosclerosis can lead to ischemia of downstream tissues and subsequent
hypoxia304. This induces mitochondrial damage and electrolyte imbalance304. During the reperfusion state, such as upon revascularization surgery, these deficits promote ROS generation, oxidative stress, and a downward cascade of cell damage and cell death304. From a clinical perspective,
IRI can lead to serious complications, such as hibernating myocardium, acute heart failure, cerebral dysfunction, systemic inflammatory response syndrome, and multiple organ dysfunction
syndrome304. Flow-mediated dilation was assessed before and after a bout of ischemia-reperfusion of the brachial artery in a recent study using IRI to induce endothelial dysfunction in the
M/EF and LF phases in ten NC women305. Ischemia-reperfusion injury significantly reduced
FMD in the M/EF phase, but FMD was preserved following IRI in the LF phase305. As such, protection from endothelial damage following acute insult in NC women may also have a basis in
acute estradiol concentration.
Summary. Most findings support the principle of increased microvascular or endothelial
function during phases of higher compared with lower estradiol concentrations. However, some
reports indicate no differences between phases with differing estradiol concentrations, including
studies within the cutaneous microvasculature (3 of 5 studies report no or marginal differences
with estradiol concentrations). Interestingly, endothelial function could be most impaired just
following ovulation, which coincides with complex changes in many endogenous hormones, including testosterone. The effect of changing endogenous hormone concentration on in vivo NO
bioavailability is not well-defined. Further, in women, greater defenses against acute insult may
be mediated by estradiol.
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In Vivo Microvascular and Endothelial Function in Women Using Oral Contraceptives
This section will provide an overview of the literature regarding OCP use and in vivo
function of 1) the cutaneous microvasculature, 2) other microvascular beds, and 3) the endothelium in conduit vessels.
Cutaneous Microvascular Function. Studies investigating cutaneous microvascular vasodilation and exogenous hormone changes in premenopausal women have also yielded inconsistent results. One study has directly investigated the effect of exogenous sex hormones on endothelium-dependent vasodilation in the cutaneous microvasculature21. This study tested 6
women during low and high hormone phases of combination OCP use (any generation). In response to local heating to 42°C, endothelium-dependent vasodilation was increased during the
high hormone phase (76 ± 3 %CVCmax) compared with the low hormone phase (68 ± 4
%CVCmax)21. Though this was a marginal difference, it was statistically significant, and there
was a large effect size (d = 2.3).
Other studies have assessed cutaneous endothelium-dependent vasodilation in response to
iontophoresis of ACh306, 307. One study found no differences between or within NC women or
women using OCP of any generation306, where NC women were tested during M, LF, and ML
phases and women using OCP were assessed twice during the high hormone phase. The second
study found women using OCP containing desogestrel or drospirenone had increased vasodilation during the high hormone phase compared with the low hormone phase, whereas women using levonorgestrel OCP or NC women showed no difference between the two time points307.
Again, these studies may not accurately reflect the effect of OCP on the NO pathway, though
they do provide insight on endothelial function.
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Further, two studies have employed pharmacological suppression of endogenous hormones in NC women, via a GnRH antagonist (GnRHant), and then administered estradiol and/or
progesterone. In these studies, estradiol was administered via transdermal patch and progesterone
was administered orally (if used)308, 309. Therefore, these studies do not provide direct perspective
on the effect of combination OCP on cutaneous microvascular function, though they do provide
context for the acute interruption of the HPO axis followed by administration of exogenous hormones. One study found marginal differences in cutaneous vasodilation with estradiol and progesterone administration alone and in combination308. In the second study, estradiol increased
thermal hyperemia during GnRHant (control: 83 ± 9 %CVCmax, estradiol: 89 ± 8 %CVCmax)309.
From these data, the effect of regular OCP use on cutaneous microvascular function remains unclear, but it does appear route of administration of exogenous hormone may be important to
downstream effects.
Other Microvascular Beds. In a comparison of OCP users (tested on d 12 of pill
pack/high hormone, any generation except first) and NC women (tested on d 12 of natural menstrual cycle), NC women may have greater percent change and absolute forearm endotheliumdependent vasodilation compared with OCP users29. Though not statistically significant (p-value
not provided), effect sizes for mean differences of both percent change (NC women: 828 ±
137%; OCP users: 701 ± 114%) and absolute (NC women: 35.6 ± 6.3 mL/min per 100 mL; OCP
users: 25.3 ± 4.3 mL/min per 100 mL) endothelium-dependent vasodilation were large (d = 1.0,
d = 2.1, respectively)29. However, when NC women during the M/EF phase were compared with
OCP users during a low hormone phase, OCP users showed greater (any generation)28 or no
change (third generation)310 in forearm microvascular function.
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Conduit Vessel Endothelial Function. Within OCP users, conduit vessel endothelial function appears to fluctuate with EE dose and included progestin. A study by Friedman et al. portrays this nicely, although a power calculation for sample sizes included is not reported311. This
analysis included 16 women using estrane or gonane formulations (i.e., first, second, or third
generation OCPs) and 7 women using drospirenone formulations (i.e., fourth generation). Between these 23 women, there were 16 women using lower dose preparations (0.02-0.025 mg EE)
and 7 women using higher dose preparations (0.03-0.035 mg EE). Progestin type was an independent predictor of FMD, showing a mean difference of 3.26% between estrane/gonane users
and drospirenone users (greater in drospirenone users). Ethinyl estradiol dose was nearly a significant predictor of FMD (p = 0.057), with a mean difference of 2.97% between lower dose and
higher dose preparations (group values not reported). In this study, all women were tested during
the low hormone phase; as such, it is unclear if the effect within this study would remain during
the high hormone phase of use.
Within the literature, the effect of OCP on FMD does appear to depend on generation of
progestin. After six months of second generation OCP use, FMD decreases by 29% (10.1 ± 4.2%
vs. 7.2% 4.6%)312. Further, second generation OCP users have reduced FMD compared with NC
women313, 314; of note, one of these investigations took place when OCP women were in a high
hormone phase and NC women were in the EF phase (i.e., low hormone phase)313 and the other
did not report phase for either group314. After six months of fourth generation OCP use though,
there is a non-significant 11% reduction (7.8 ± 3.3% vs. 7.0 ± 2.8 %, d = 0.3, p = 0.35)312 or no
difference (7.17 ± 0.68 vs. 7.04 ± 0.85)315 in FMD. Flow-mediated dilation is also similar between fourth generation OCP users (7.04 ± 0.85%) and controls (7.64 ± 0.83%), although there is
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a medium-large effect size between groups (d = 0.7)315. However, groups of women using a variety of OCPs versus NC women show no difference in FMD between groups205, 288, though one of
these assessed the average scaled FMD across three time points during a one month cycle and
had a medium effect size (OC women: 6.5 ± 2.0% vs. NC women: 5.5 ± 2.2%, p = 0.15, d =
0.48)288.
In low dose formulations (i.e., EE dose of 0.03-0.035 mg), there are mixed findings for
phasic experiments across OCP generation. There is no difference in FMD between low and high
hormone phases in women using low dose second generation OCP20, 307. However, women using
low dose third or fourth generation OCP formulations show increased FMD during the high hormone phase compared with the low hormone phase18, 19, 307. Findings in women using very low
dose formulations (EE dose of 0.025 mg or less) are more congruent with each other. Women using a very low dose second generation or third generation OCP formulations have reduced FMD
during the high hormone phase compared with the low hormone phase19, 20. Although the phasic
difference in third generation OCP users (high: 5.86 ± 0.63%; low: 6.56 ± 0.70%) did not reach
statistical significant, there was a large effect size (p = 0.11, d = 1.1)19. Further, in a cohort of
women using a variety of OCPs, FMD during the low hormone phase of OCP use (7.8 ± 2.4%)
was greater than FMD during the high hormone phase of OCP use (6.8 ± 2.0%, d = 0.45) and the
low hormone phase of NC women (M/EF, 6.9 ± 3.5%, d = 0.30)288.
Participant characteristics may mediate the effect of exogenous hormones on functional
measures, such as FMD. For instance, in a study assessing FMD before and after 7 days of 0.03
mg EE exposure, when data was stratified by blood pressure status (normotensive or hypertensive) or body composition (lean or obese), individual responses were highly variable316. While
not statistically significant, more obese women appear to show improvements in FMD with EE
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exposure than lean women. Further, hypertensive women showed a statistically significant increase in FMD, and normotensive women showed a statistically significant decrease in FMD,
with EE exposure.
Summary. The literature regarding microvascular and endothelial function in women using OCP is incongruent and may depend on OCP formulation. Generation of progestin and EE
dose may affect in vivo function, but the literature remains unclear. Specifically, use of second
generation OCPs results in no change or decreases in endothelial function. Use of third or fourth
generation OCPs results in no change or a decrease in endothelial function compared with NC
women; however, regarding phasic differences, there is support for both improved and reduced
function during high hormone phases compared with low hormone phases. Samples including
women using a variety of OCPs yield inconsistent results as well, where reports suggest increased, decreased, or no change in endothelial function between phases or compared with NC
women. Interestingly though, there is support (3 of 3 relevant comparisons) for an increase in
microvascular or endothelial function in women using OCPs of any variety compared with NC
women when both subgroups are in their respective low hormone phases28, 29, 288. Regardless of
inconsistencies in in vivo function, the potential impact of OCP use on underlying mechanistic
pathways of endothelial function, including the NO pathway, remain unknown. Further, the relationship between OCP use and demographic/hemodynamic descriptors on endothelial function
remain unclear.
Lifestyle Behaviors and Endothelial Function
As previously stated, some lifestyle behaviors have supported effects on endothelial function and/or underlying pathways. The impact of 1) physical activity, 2) sleep, 3) dietary intake,
and 4) stress will be briefly discussed in the sub-sections to follow.
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Physical Activity. Physical activity is known to improve many aspects of physiologic
well-being in humans, including endothelial function. Laminar vascular shear stress increases
during exercise, due to an increase in blood flow51. In turn, shear stress increases eNOS expression and NO production, decreases circulating ET-1, increases SOD and GPx expression, and decreases NADPH oxidase activity51, 317-321. As such, regular exercise creates an environment of
greater NO bioavailability, through increased NO synthesis and decreased ROS.
Sleep. Recently, poor quality or quantity of sleep has been associated with endothelial
dysfunction. Shorter sleep duration is associated with decreased FMD in adults54, 322. Further, a
sleep duration less than 7 hr/night is linked with microvascular endothelial dysfunction. This includes a 20% reduction in ACh-induced vasodilation56 and a 3-fold greater response to an ET-1
receptor antagonist323, indicating significant impact of ET-1. Women may be more susceptible to
endothelial dysfunction associated with reduced sleep, as < 7 hr/night of sleep is associated with
reduced microvascular function, while men showed no difference with this sleep duration55.
Other mechanisms underlying endothelial dysfunction with reduced sleep include increased ROS
generation, inflammation, and/or sympathetic activity54.
Dietary Intake. Many components of the human diet possess anti-inflammatory or antioxidant effects, which can influence endothelial or vascular function. Berry consumption is associated with improved vascular function and underlying mechanisms57, 69, 324-327. Diets abundant in
fruits and vegetables have positive effects on CRP and other endothelial markers including intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and Eselectin. Cheese consumption ameliorates endothelial dysfunction associated with high sodium
diets and appears to improve endothelial function in vulnerable populations via antioxidant
mechanisms328, 329. Egg consumption is linked to increased FMD and may reduce oxidative
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stress58. However, red meat and refined grain intake is associated with markers of endothelial
dysfunction, including increased ICAM-1, VCAM-1, and E-selectin60, 330.
Stress. Stress is a consistent feature in worse health outcomes and disease development,
and, consistently, can induce endothelial dysfunction61. Psychosocial stress is linked to increased
cortisol and CRP62-65, which are precursors to oxidative stress. Stress increases other pro-inflammatory cytokines, including interleukin (IL)-1, IL-6, and tumor necrosis factor-α (TNFα)331.
Further, chronic stress is associated with increased ICAM-1 and reduced FMD332.
Conclusions
Based on this review of literature, it is established that sex hormones can influence endothelial function and endothelium-dependent signaling pathways. However, in premenopausal
women, the impact of endogenous and exogenous hormones may differ mechanistically. While
various studies have investigated the effect of endogenous and exogenous hormones on in vivo
endothelial function in women, the effect of these hormone exposures on underlying mechanisms
has yet to be delineated. Namely, exogenous hormone exposure during OCP use exacerbates oxidative stress and inflammation in otherwise healthy, young women. The literature suggests these
changes have implications on other molecular pathways of endothelial function, specifically the
NO pathway, in other populations. Therefore, this dissertation was designed to assess mechanisms of cutaneous microvascular endothelial function and NO bioavailability in premenopausal
women who are either NC or using OCP. Through the completion of four projects, this dissertation informs endothelial function between women in low hormone phases and age-matched men,
between NC women and women using OCP in respective low hormone phases, between low and
high hormone phases of OCP use, and before and after cessation of OCP use.
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3 METHODOLOGY
The following sections will address the conceptual framework of the included studies, inclusion and exclusion criteria for participation, instruments used, procedures and specific experimental protocols, and expectations.
Conceptual Framework
Proposed Models. Experimental design of the studies included in this dissertation is
based on two proposed models. Proposed Model 1 maps how endothelial function may be affected in women using OCP compared with NC women or men. This model is based on molecular alterations of endothelial function with exogenous hormones versus sex-based primary endogenous hormones. Considering endogenous
estradiol has
anti-inflammatory and antioxidant properties,
relative changes
in estradiol concentration appears to linearly
affect endothelial function. However, considering circulating exogenous hormones (via OCP) are
associated with increased inflammation and oxidative stress, relative changes in exogenous hormone concentration may inversely affect endothelial function.
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Proposed Model 2 hypothesizes how OCP use may affect the mechanistic pathways underlying endothelial function in the microvasculature. This includes proposed alterations to endothelium-dependent pathways, including the NO, COX, and EDHF pathways. This model is based
on molecular impacts of oxidative stress and inflammation, as well as interaction and compensation that occurs within and between endothelium-dependent pathways.

Experimental Design. Four projects focused on endothelium-dependent vasodilation and
NO bioavailability in premenopausal women were completed. For Project 1, we recruited NC
women, women using monophasic, combination OCP, and men. Project 1 employed a cross-sectional design. For Projects 2 and 3, we recruited women using monophasic, combination OCP.
Projects 2 and 3 employed a repeated measures design. Project 4 is a case study by design and
used a repeated measures design.
Participants
Participants were be recruited from Georgia State University student and staff population
and the surrounding metro-Atlanta area. All participants gave both written and verbal informed
consent. All protocols conformed to the guidelines set forth in the Declaration of Helsinki.
Inclusion and Exclusion Criteria. All women participants were between the ages of 18-30
y, and all men participants were between the ages of 18-40 y, to minimize known age-related
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decrements in endogenous estradiol production in women and NO-dependent vasodilation in
adult humans. Participants were healthy as assessed by health history questionnaire. Participants
were not taking any medications, including antioxidant supplements or regular non-steroidal
anti-inflammatory drug use, except for women taking OCP. Women in the NC group were not
currently using OCP or used OCP within the past one year. NC women had a normal menstrual
cycle with no cycle lasting longer than 40 d over the past six months288. Women in the OCP
group were taking monophasic, combined OCP for at least three months259.
Exclusion criteria included current tobacco/nicotine use (including e-cigarettes), regular
tobacco/nicotine use within the past five years (defined as use at least 3 times per week), and alcohol consumption averaging more than 10 grams of alcohol per day (as this quantity has been
linked to alterations in endogenous sex hormone concentrations in women333, 334). Further exclusion criteria included a history of disease (cardiovascular, metabolic, cancer or chemotherapy
treatment, neurologic disorders, skin disorders, or respiratory disorders), active COVID-19 infection or < 1 mo post-COVID-19 infection, long-lasting symptoms following COVID-19 infection,
current pregnancy, current breast-feeding status, or use of an extended formulation OCP.
Instruments
In the following sub-sections, instruments used within the experimental protocols will be
described. The 1) lifestyle behavior questionnaires were only administered to women participating in Project 3. However, the remaining instruments were used in the remainder of all protocols,
including 2) health history questionnaire, 3) local heater units, 4) laser-Doppler flowmetry, and
5) intradermal microdialysis.
Lifestyle Behavior Questionnaires. Three questionnaires regarding lifestyle behaviors
were administered to each participant participating in Project 3 only (only women using OCP,
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see Appendix). These questionnaires included, 1) the College Student Stress Scale335, to assess
frequency and severity of subjective stress in 11 distinct categories (where only one of these is
directly related to academic-related stress), 2) the Five City Project Physical Activity Recall324,
336, 337

, to assess indices of sleep quantity and moderate-to-vigorous intensity overall physical ac-

tivity (not only structured exercise), and 3) a validated 7-day food frequency questionnaire324, to
assess dietary intake (assessing both frequency and quantity) of a variety of foods. All questionnaires assessed parameters over the 7 days prior to the date of experimental testing.
Health History Questionnaire. All included participants completed a health history questionnaire routinely used in our lab to assess current and past health history (see Appendix). This
included history of cardiovascular diseases (i.e., hypertension, hyperlipidemia, dyslipidemia, or
presence of overt CVDs), metabolic diseases (i.e., diabetes mellitus, thyroid disorders, etc.), cancer (or prior cancer treatment via chemotherapy or radiation), skin disorders (i.e., psoriasis, eczema, etc.), known nerve damage, chronic pain syndrome, or previous case of COVID-19.
Women participants were also asked questions regarding their natural menstrual cycle or specifics about their OCP use.
Local Heater Units. Local heater units (VHP1 heater units and VMS-HEAT controller;
Moor Instruments, Axminster, UK) were attached to the skin with adhesive rings and were used
to control local skin temperature. The placement of the local heater unit in the experimental setup is illustrated in Figure M1 (page 62). Heating units were set to 33°C to clamp local skin temperature at experimental sites for baseline measurements. A rapid local heating protocol of the
skin was used to elicit endothelium-dependent dilation of the cutaneous microvasculature. Temperature of each local heater was increased from 33°C to 39°C at a rate of 0.1°C/sec136. This tem-
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perature is well below the point of pain but causes significant dilation of the cutaneous microvasculature. Skin blood flow was allowed to reach an established plateau (~40-45 minutes from the
initiation of local heating). Following the establishment of a plateau, the skin was heated to 43°C
to quantify site-specific maximal vasodilation to standardize skin blood flow measurements.
Laser-Doppler Flowmetry (LDF). A LDF probe was held within each local heater unit to
obtain a site-specific index of skin blood flow. The placement of the LDF probe in the experimental set-up is illustrated in Figure M1 (page 62). The LDF technology is based on laser beam
reflection. When a laser light beam encounters a moving blood cell, the wavelength is changed
(i.e., Doppler shift), reflected, and quantified. The absolute magnitude and frequency of wavelength changes relate to the quantity and velocity of moving blood cells within a given spatial
area. This index of skin blood flow is recorded in arbitrary flux units (i.e., red blood cell, RBC
flux). The gold standard in cutaneous microvascular studies is to then standardize RBC flux to
mean arterial pressure (MAP; cutaneous vascular conductance, CVC) and then further as a percentage of site-specific maximal vasodilation (%CVCmax) to account for inter- and intra-participant heterogeneity338.
Intradermal Microdialysis. Intradermal microdialysis is a minimally invasive technique
to administer pharmacological agents directly to the cutaneous microvasculature, allowing for
pharmacological dissection of underlying mechanisms of vasodilation. The orientation of the intradermal microdialysis fiber in the experimental set-up is illustrated in Figure M1 (page 62). To
place the intradermal microdialysis fibers (CMA 31; Harvard Apparatus, Hollister, MA), an ice
pack is first used to numb the skin for 5-10 minutes339. The skin is cleansed with a sterile alcohol
wipe over a marked entry and exit point, about 1 cm apart. A sterile, 23-gauge needle is inserted
into the dermal layer of the skin and advanced to the exit point. The microdialysis fiber is

62
threaded through the lumen of the needle, the needle is withdrawn from the skin, and a ~1-cm
long, semi-permeable membrane included in the microdialysis fiber is left in place under the
skin.
Fiber placement was followed by approximately 30-60 minutes of trauma resolution from
needle insertion. Pharmacological agents were infused for at least 30 min before beginning any
experimental protocol. All pharmacological agents were diluted in sterile lactated Ringer’s solution and drawn through filter needles (BD Filter Needle; Becton Dickinson, Franklin Lakes, NJ).
All perfusates were administered at a rate of 2 μL/min (Beehive Controller and Baby Bee syringe
pumps; Bioanalytical Systems, West Lafayette, IN). Regardless of protocol, site-specific maximal vasodilation was elicited via 28 mM sodium nitroprusside (SNP, exogenous NO donor) and
heating of the skin to 43°C.
Figure M1. Illustrative schematic of the local heater unit, laser-Doppler flowmetry probe, and intradermal microdialysis fiber. RBC, red blood cell.
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Procedures
Two distinct experimental protocols were completed to assess the five specific aims outlined above (see: Purpose). Before any experimental testing, participants were asked to refrain
from alcohol consumption, caffeine consumption, and vigorous exercise for at least 12 hours and
from high-sugar or high-fat meals for at least 2 hours.
Experimental Protocol 1. Protocol 1 was utilized in Project 1 (to address Specific Aim 1
and Specific Aim 2) and Project 4 (to assess Specific Aim 5). For Project 1, this protocol was
used to evaluate endothelium-dependent vasodilation and the contribution of NO to dilation in
young, healthy, premenopausal women (NC or using OCP) during a respective low hormone
phase and a group of similar age men. Women who were NC were tested during d 2-5 of the natural menstrual cycle (i.e., M/EF)170, when circulating concentrations of both endogenous estradiol and progesterone are low. Women using OCP were tested during d 1-2 of placebo pills170, as
this should correspond to low circulating concentrations of exogenous EE and progestin, as well
as low circulating endogenous estradiol and progesterone. For Project 4, this protocol was used
to evaluate endothelium-dependent vasodilation and the contribution of NO to dilation in one
young, healthy, premenopausal woman across the transition from OCP use to NC. This included
three assessments (one low hormone and two high hormone) during OCP use and three assessments (one low hormone and two high hormone) following OCP cessation.
Height and weight were measured using a digital scale with a platform stadiometer
(Healthometer Professional, Pelstar; Alslip, IL, USA). All women participants were required to
submit a urine pregnancy test (McKesson hCG Combo Test Cassette, Consult Diagnostics; Richmond, VA) to confirm negative pregnancy status prior to any experimental testing session. Dur-
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ing the protocol blood pressure was measured from the contralateral (respective to the experimental, right) arm using an automated brachial oscillometric device, and heart rate was derived
from pulse detection (Welch Allyn Vital Signs Series 6000; Skaneatelles Falls, NY). Blood pressure and heart rate measurements were made every 10 min and mean arterial pressure (MAP)
was calculated as one-third pulse pressure plus diastolic pressure.
One microdialysis fiber was placed in the dorsal forearm of each participant, as described
above. The site was first be perfused with sterile lactated Ringer’s. One local heater was placed
on the skin above the microdialysis fiber site, and an LDF probe was placed within the heater. A
rapid local heating protocol was completed as detailed above. Once a plateau to local heating
was achieved (~30-40 min after intiation of rapid local heating protocol), 20 mM L-NAME (nonselective NOS inhibitor) was infused to directly quantify the contribution of NO to endotheliumdependent dilation. The heaters remained at 39°C through the infusion of L-NAME, and LNAME was infused until skin blood flow reached a new plateau (termed the post-L-NAME plateau, within approximately 20-30 min). Following the establishment of the post L-NAME plateau, maximal vasodilation was elicited as described above. Following completion of the protocol, the microdialysis fibers were appropriately removed, sites were cleaned with sterile alcohol,
and the area was covered with sterile gauze.
Experimental Protocol 2. Protocol 2 was utilized in Project 2 and 3 (to address Specific
Aim 3 and Specific Aim 4). For Project 2, this protocol was used to evaluate mechanisms underlying endothelium-dependent vasodilation during a low and high hormone phase of monophasic,
combined OCP use in young, healthy, premenopausal women. Women were tested during a low
hormone phase and a high hormone phase in random order: 1) low hormone phase, during d 1-2
of placebo pills170, and 2) high hormone phase, during d 3-6+ of active pills, when circulating
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concentrations of both exogenous EE and progestin are elevated170. Experimental testing sessions
were separated by at least 7 days to allow intradermal microdialysis sites to heal between sessions. For Project 3, this protocol was used to obtain endothelium-dependent and NO-dependent
vasodilation measurements for correlation analysis with indices of lifestyle behaviors.
Height and weight were measured using a digital scale with a platform stadiometer
(Healthometer Professional, Pelstar; Alslip, IL, USA). All women participants were required to
submit a urine pregnancy test (McKesson hCG Combo Test Cassette, Consult Diagnostics; Richmond, VA) to confirm negative pregnancy status prior to any experimental testing session. During the protocol blood pressure was measured from the contralateral (respective to the experimental, right) arm using an automated brachial oscillometric device, and heart rate was derived
from pulse detection (Welch Allyn Vital Signs Series 6000; Skaneatelles Falls, NY). Blood pressure and heart rate measurements were made every 10 min and MAP was calculated the same as
described above.
Four microdialysis fibers were placed in the dorsal forearm of each participant, as described above. All four sites were first perfused with sterile lactated Ringer’s. The four
experimental sites were then randomized to one of the four experimental conditions: 1) lactated
Ringer’s, to serve as control, 2) 10 mM ketorolac, a non-selective COX inhibitor117, 119, 3) 50
mM TEA, a non-specific KCa channel inhibitor136, 308, and 4) 10 mM ketorolac + 50 mM TEA in
combination. A local heater was placed on the skin over each microdialysis fiber placement and
an LDF probe was placed within each heater. The remainder of Protocol 2 took place in exact
congruence with the remainder of Protocol 1, as detailed above.
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Data Analysis. The primary outcome variables for all projects were %CVCmax and
%NO-dependent vasodilation (defined below). Other outcome variables included indices of lifestyle behaviors. RBC flux was transformed to CVC by dividing by MAP, then standardized as a
percentage of site-specific maximal vasodilation (to achieve %CVCmax). The NO contribution to
dilation (%NO-dependent vasodilation) was calculated using the following equation.
(%𝑪𝑽𝑪𝒎𝒂𝒙 𝒂𝒕 𝒍𝒐𝒄𝒂𝒍 𝒉𝒆𝒂𝒕𝒊𝒏𝒈 𝒑𝒍𝒂𝒕𝒆𝒂𝒖 − %𝑪𝑽𝑪𝒎𝒂𝒙 𝒂𝒕 𝒑𝒐𝒔𝒕 − 𝑳 − 𝑵𝑨𝑴𝑬 𝒑𝒍𝒂𝒕𝒆𝒂𝒖)
× 𝟏𝟎𝟎
%𝑪𝑽𝑪𝒎𝒂𝒙 𝒂𝒕 𝒍𝒐𝒄𝒂𝒍 𝒉𝒆𝒂𝒕𝒊𝒏𝒈 𝒑𝒍𝒂𝒕𝒆𝒂𝒖

Statistical Analysis. Sample size was determined with a priori power analysis. Effect
sizes were specified based on preliminary data collected in our laboratory. Our initial preliminary
data suggested a large effect size (d = 1.4) of the mean difference in endothelium-dependent dilation between women (either NC or women using OCP) in their respective low hormone phases
and age-matched men (-18 %CVCmax in women vs. men). Assuming an α level of 0.05 and 95%
power, this resulted in a sample size of n = 14 per group. To account for potential differences in
standard deviation with a larger study sample, we increased the sample size by 25%, to result in
a final sample size of n = 18 per group. The further subgroup analysis was based on preliminary
data for the NO contribution to dilation between subgroups of women (NC women vs. women
using OCP). Our preliminary data suggested a large effect size (d = 2.3) of the mean difference
in NO contribution to dilation between NC women and women using OCP in their respective
low hormone phases (-31 %NO in NC women vs. women using OCP). Assuming an α level of
0.05 and 95% power, this resulted in a sample size of n = 7 per group. To account for potential
differences in standard deviation with a larger study sample, we increased the sample size by
25%, to result in a final sample size of n = 9 per group.
Preliminary data from our lab suggested a large effect size (d = 1.9) of the mean difference of NO contribution to dilation between the low hormone (LH) and high hormone (HH)
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phase of OCP use (-16 %NO in HH phase vs. LH). Assuming an α level of 0.05 and 95% power,
this resulted in a sample size of n = 9 per group. To account for potential differences in standard
deviation with a larger study sample, we increased the sample size by 25%, to result in a final
sample size of n = 12 per group.
All outcome data were first tested for normality (Shapiro-Wilk test) and equal variance
(Levene test). Effect size was calculated using Cohen’s d when variance and sample size were
similar. Hedge’s g was used to assess effect size when sample sizes were unequal. When appropriate, and if data were normal, data were analyzed using independent samples T-tests, one-way
analysis of variance (ANOVA), or two-way ANOVA with repeated measures. Tukey correction
factors were used to account for multiple pairwise comparisons. When data were not normal, appropriate non-parametric tests were used, including Mann-Whitney tests or Kruskal-Wallis tests,
and Dunn’s correction factors were used to account for multiple comparisons. Data are presented
as mean ± SD. Additionally, correlation analysis was completed for exploratory analysis with indices of lifestyle behaviors.
Expectations
Expected potential problems, and outcomes, are addressed below.
1) We anticipated that there may be difficulties with participant recruitment, considering
challenges related to the COVID-19 pandemic. There were, indeed, difficulties with participant
recruitment, regardless of persistent recruitment flyer distribution, classroom visits, and contacts
within and outside of Georgia State University helping to distribute recruitment materials. The
originally proposed studies were amended yet addressed the same overall purpose. While projects were amended, all completed studies were appropriately powered for analyses, planned to
achieve ≥ 80% power at an alpha level of 0.05.
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2) We anticipated potential participant drop out for those participants completing Protocol 2, because this protocol included two visits to the laboratory. However, no participants were
lost to follow up. To aid retention, we scheduled both visits to the laboratory at the same time
and regularly checked in with participants between scheduled visits.
3) We did not monitor luteinizing hormone or FSH, possibly allowing us to miss relevant
physiological interpretations. Most evidence does suggest estradiol is the primary hormone contributing to cardio- and vasculo-protection in women, but it is possible that there are interactions
of these hormones on vascular and/or endothelial function. As the amended studies only included
NC women during the M/EF phase, luteinizing hormone and FSH should have minimal contributions, because they should both be low during this phase.
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4 RESULTS: PROJECT 1
There has been minimal assessment of sex differences in endothelium-dependent vasodilation within the skin26, 27, 270. Two studies have used a standard rapid local heating protocol to
42°C26, 136, 270, where heating to 42°C elicits near maximal (~85-95 %CVCmax) vasodilation
within the skin338. Investigators may decide to use a more recently established rapid local heating
protocol to 39°C, as this protocol achieves a lower %CVCmax (~55-60 %CVCmax) of the local
heating plateau, minimizing a potential ceiling effect in the response27, 136, 272, 273 . This result allows investigators to assess interventions that may increase endothelium-dependent responses.
Importantly, local heating to 39°C elicits a vasodilation response that is still largely dependent on
NO, and may even be more dependent on NO (~80% vs. ~50-70% when heating to 42°C)136.
One study has assessed sex differences in cutaneous microvascular vasodilation using a rapid local heating protocol to 39°C, but this study may not have been appropriately powered for this
subgroup analysis27.
Further, there is indirect support for differing NO bioavailability between NC women and
women using OCP during respective low hormone phases26, 27. There is also support for opposite
relationships between microvascular function and circulating endogenous or exogenous hormone
levels (i.e., lower endogenous hormone phases yield lower microvascular vasodilation while
lower exogenous hormone phases yield higher microvascular vasodilation, and vice versa with
high hormone phases)28, 29. Therefore, the decline in circulating exogenous hormones during the
low hormone phase of OCP use may temporarily alleviate endothelial distress, possibly caused
by inflammation or oxidative stress, and allow greater NO bioavailability and endothelium-dependent vasodilation during this phase. However, there has yet to be a structured investigation to
determine if these subgroups of women represent a homogenous sample regarding endothelial
function.
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The purpose of Project 1 was to characterize cutaneous microvascular endothelium-dependent and NO-dependent vasodilation (to rapid local heating to 39°C) between women in low
hormone phases of their respective hormonal state (either NC or using OCP) and men. A secondary purpose of the project was to compare endothelium-dependent and NO-dependent vasodilation between subgroups of NC women, women using OCP, and men, in a planned subgroup analysis. We hypothesized that 1) the magnitude of endothelium-dependent vasodilation would be
similar between women in low hormone phases and age-matched men, 2) NO-dependent vasodilation would be similar between women in low hormone phases compared with age-matched
men, 3) endothelium-dependent vasodilation would be similar between the two subgroups of
women (i.e., NC women and women using OCP), and 4) NO-dependent vasodilation would be
greater in women using OCP compared with NC women in their respective low hormone phases.
Participant Characteristics
Participant descriptive information is shown in Table 1A as mean ± SD.
Table 1A. Participant characteristic information.

Women
(n = 18)

Men
(n = 18)

22 ± 3

23 ± 5

2 H / 8 NHB / 8 NHW

10 NHB / 8 NHW

Height (m)

1.66 ± 0.07

1.80 ± 0.07

Weight (kg)

70.1 ± 17.0

80.3 ± 11.9

Body Mass Index (BMI, kg/m2)

26 ± 6

25 ± 3

Resting Heart Rate (bpm)

70 ± 6

60 ± 7

Systolic Blood Pressure (mmHg)

114 ± 6

112 ± 8

Diastolic Blood Pressure (mmHg)

73 ± 4

71 ± 8

Mean Arterial Pressure (mmHg)

86 ± 4

85 ± 8

Age (y)
Self-identified race/ethnicity*

*H, Hispanic. NHB, non-Hispanic Black. NHW, non-Hispanic White.
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All NC women were tested on d 2 (n = 2), d 3 (n=3), d 4 (n = 3), or d 5 (n = 1) of the natural menstrual cycle. All women using OCP were tested on d 1 (n = 3) or d 2 (n = 6) of placebo
pills. Details about the OCPs participants were using, including components, dosages, and generation, are shown in Table 1B. All participants were taking monophasic, combination formulations for at least 3 mo.
Table 1B. OCP Details: Included Components, Dosages, and Generation.
Number of Participants

EE Dose

Progestin Dose

Generation

2

0.01 mg EE

1 mg norethindrone acetate

1st

2

0.02 mg EE

1 mg norethindrone acetate

1st

1

0.035 mg EE

0.25 mg norgestimate

2nd

1

0.03 mg EE

0.15 mg desogestrel

3rd

2

0.02 mg EE

3 mg drospirenone

4th

1

0.03 mg EE

3 mg drospirenone

4th

Women in Low Hormone Phases Versus Age-Matched Men
Data are shown as mean ± SD. Maximal and baseline skin blood flow data for the complete cohort is shown in Table 1C. There was no effect of group on maximal skin blood flow;
however, baseline blood flow was greater in men than women (p = 0.01).
Table 1C. Maximal and baseline skin blood flow.
Maximal Blood Flow (flux/MAP)

Women
(n = 18)
2.67 ± 0.68

Men
(n = 18)
2.42 ± 0.85

Baseline Blood Flow (%CVCmax)

12 ± 5

17 ± 7 *

Initial peak data are shown in Figure 1A (following page). The magnitude of the initial
peak was greater in men (58 ± 18 %CVCmax) than in women (41 ± 13 %CVCmax, p < 0.01). Plateau data are shown in Figure 1B (following page). The magnitude of the plateau to local heating
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was also greater in men (71 ± 16 %CVCmax) than in women (52 ± 20 %CVCmax, p < 0.01). PostL-NAME plateau data are shown in Figure 1C (below). The post-L-NAME plateau was greater
in men (34 ± 10 %CVCmax) than in women (18 ± 10 %CVCmax, p < 0.01), suggesting men were
less responsive to NOS inhibition with L-NAME. The calculated NO contribution to vasodilation
is shown in Figure 1D (below). Though it did not reach statistical significance, this resulted in
lower NO-dependent vasodilation in men (52 ± 11 %NO) compared with women (63 ± 17 %NO,
p = 0.051, d = 0.8).

Subgroup Analysis
A planned, appropriately powered, subgroup analysis for the responses to rapid local
heating between NC women, women using OCPs, and men was also performed. Data are shown
as mean ± SD. Maximal and baseline skin blood flow are shown below in Table 1D. Although
not statistically significant (p = 0.1), there were medium-large effect sizes for the mean difference in maximal vasodilation for women using OCP compared with men (g = 0.6) and compared
with NC women (d = 0.8). There was no main effect of group for baseline blood flow.
Table 1D. Maximal and baseline
skin blood flow in 3 subgroups.

NC Women
(n = 9)

Women Using OCP
(n = 9)

Men
(n = 18)

Maximal Blood Flow (flux/MAP)

2.44 ± 0.55

2.91 ± 0.75

2.42 ± 0.85

Baseline Blood Flow (%CVCmax)

11 ± 6

12 ± 3

17 ± 7

73
The initial peak was 38 ± 16 %CVCmax in NC women, 43 ± 10 %CVCmax in OCP
women, and 58 ± 18 %CVCmax in men (Figure 1E, below). There was a main effect of group for
initial peak (p = 0.01), where initial peak was greater in men than NC women (p = 0.02), but the
comparison between men and women using OCP did not reach statistical significance (p = 0.08,
g = 0.7). The plateau was 48 ± 21 %CVCmax in NC women, 56 ± 19 %CVCmax in OCP women,
and 71 ± 16 %CVCmax in men (Figure 1F, below). There was a main effect of group for plateau
(p = 0.01), where plateau was greater in men compared with NC women (p = 0.01). The post-LNAME plateau was 22 ± 11 %CVCmax in NC women, 14 ± 7 %CVCmax in OCP women, and 34
± 10 %CVCmax in men (Figure 1G, below). There was a main effect of group for post-L-NAME
plateau (p < 0.01), where men displayed a greater magnitude of post-L-NAME plateau compared
with NC women (p = 0.01) and OCP women (p < 0.01), again suggesting men were less responsive to NOS inhibition with L-NAME than both subgroups of women. Though the p-value did
not reach statistical significance, there was a large effect size for post-L-NAME plateau between
NC women and OCP women (p = 0.15, d = 0.9). The NO contribution was 52 ± 14 %NO in NC
women, 74 ± 11 %NO in OCP women, and 52 ± 11 %NO in men (Figure 1H, below). There was
a main effect of group for NO contribution to the plateau (p < 0.01), where OCP women displayed greater calculated %NO compared with NC women (p < 0.01) and men (p < 0.01).
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RESULTS: PROJECT 2
There has been minimal study of mechanisms regulating endothelial function in premenopausal women using OCP. There is indirect support for an increase in endothelial function and
NO bioavailability in women using OCPs during the low compared with the high hormone
phase28, 29, 288. Further, women using OCP have elevated markers of oxidative stress and inflammation compared with NC women10-12. Oxidative stress and inflammation both negatively impact endothelial function and NO bioavailability13-15. Additionally, OCP use is associated with
increased risk of thrombosis16, 17. This would collectively suggest endothelial dysfunction, including a primary impact on the NO pathway, with OCP use. As reviewed from the literature,
endothelium-dependent pathways interact and may compensate for one another during dysfunction of another pathway. Therefore, regulation through COX and/or EDHF pathways may be altered during OCP use.
The purpose of Project 2 was to assess the effect of OCP phase (either low hormone or
high hormone phase) on mechanisms underlying endothelium-dependent microvascular dilation
in premenopausal women taking monophasic, combination OCP for at least three months. We
hypothesized that 1) overall endothelium-dependent microvascular dilation will be similar between the low hormone and high hormone phase of OCP use, 2) the NO contribution to microvascular dilation will be reduced during the high hormone phase of OCP use compared with the
low hormone phase, 3) the EDHF contribution to microvascular dilation will be increased during
the high hormone phase of OCP use compared with the low hormone phase, and 4) COX inhibition will increase baseline blood flow and NO-dependent vasodilation, but not impact endothelium-dependent vasodilation, in both phases of OCP use.
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Participant Characteristics
Twelve, healthy women using OCPs were included in this study. Participant descriptive
and hemodynamic information is shown in Table 2A (below). Data are shown as mean ± SD.
Details about the OCPs participants were using, including components and dosages, are shown in
Table 2B (following page). All participants were taking monophasic, combination formulations
for at least three months. Women also reported primary reasons for originally beginning OCP
use. Some participants indicated more than one primary reason for beginning use. Reasons included acne (n = 4), contraception (n = 6), cycle regulation (n = 5), dysmenorrhea (n = 4), and
menorrhagia (n = 1). Three of 12 participants identified contraception as the sole reason for beginning OCP use.

Table 2A. Participant characteristic information.

Low Hormone Phase
(n = 12)

Age (y)
Self-identified race/ethnicity*

High Hormone Phase
(n = 12)

23 ± 4
2 A / 2 H / 3 NHB / 5 NHW

Duration of OCP Use (mo)

24 ± 29

Height (m)

1.65 ± 0.07

Weight (kg)

65.28 ± 13.05

65.21 ± 12.93

BMI (kg/m2)

23.7 ± 3.6

23.8 ± 3.5

Resting Heart Rate (bpm)

71 ± 6

75 ± 8

Systolic Blood Pressure (mmHg)

113 ± 6

111 ± 8

Diastolic Blood Pressure (mmHg)

72 ± 5

70 ± 5

Mean Arterial Pressure (mmHg)

86 ± 5

84 ± 6

*A, Asian. H, Hispanic. NHB, non-Hispanic Black. NHW, non-Hispanic White.
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Table 2B. OCP Details: Included Components and Dosages.
Number of Participants

EE Dose

Progestin Dose

Generation

2

0.01 mg EE

1 mg norethindrone acetate

1st

4

0.02 mg EE

1 mg norethindrone acetate

1st

1

0.035 mg EE

0.25 mg norgestimate

2nd

1

0.02 mg EE

0.15 mg desogestrel

3rd

1

0.03 mg EE

0.15 mg desogestrel

3rd

2

0.02 mg EE

3 mg drospirenone

4th

1

0.03 mg EE

3 mg drospirenone

4th

Maximal and Baseline Skin Blood Flow Data
No interaction effect (phase*experimental site) was found for maximal or baseline skin
blood flow. Collective maximal and baseline skin blood flow data between the low and high hormone phases is shown in Table 2C. There was a main effect of phase on maximal skin blood
flow, where maximal blood flow was greater during the high hormone compared with the low
hormone phase (p = 0.01). There was no effect of phase on overall baseline blood flow.
Table 2C. Maximal and baseline skin blood flow by
phase.
Maximal Blood Flow (flux/MAP)
Baseline Blood Flow (%CVCmax)

Low Hormone

High Hormone

2.65 ± 0.68

2.93 ± 0.82 *

16 ± 11

16 ± 12

Site-specific maximal and baseline skin blood flow data are shown in Table 2D (following page). There was no main effect of experimental site for maximal skin blood flow (p = 0.1).
There was a main effect of experimental site for baseline skin blood flow (p < 0.01), where baseline blood flow was greater at Keto sites compared with all other sites.
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Table 2D. Maximal and baseline
skin blood flow by site.
Maximal Blood Flow (flux/MAP)

Control

Keto

TEA

Keto+TEA

2.97 ± 0.72

3.02 ± 0.63

2.54 ± 0.78

2.53 ± 0.84

Baseline Blood Flow (%CVCmax)

16 ± 10

27 ± 11 *

9±7

12 ± 8

Initial Peak Data
Figure 2A shows the initial peak data
as mean ± SD. During the low hormone phase,
the initial peak was 45 ± 10 %CVCmax at Control sites, 48 ± 14 %CVCmax at Keto sites, 22 ±
14 %CVCmax at TEA sites, and 31 ± 25
%CVCmax at Keto+TEA sites. During the high
hormone phase, the initial peak was 45 ± 18
%CVCmax at Control sites, 50 ± 14
%CVCmax at Keto sites, 16 ± 11 %CVCmax
at TEA sites, and 26 ± 14 %CVCmax at
Keto+TEA sites. There was a main effect of
experimental site on initial peak, where initial peak blood flow was lower at TEA sites
compared with control and Keto sites (p <
0.01). No effect of phase or interaction effect on initial peak were found.
Individual initial peak responses to
pathway inhibition are shown in Figure 2B.
Based on mean individual responses, COX
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inhibition increased the initial peak by 7% and 26% during the low and high hormone phases,
respectively. Further, EDHF inhibition decreased the initial peak by 54% and 55% and
COX+EDHF inhibition decreased the initial peak by 44% and 37% during the low and high hormone phases, respectively.
Plateau Data
Figure 2C shows the plateau data
(mean ± SD), representing overall endothelium-dependent vasodilation. During the low
hormone phase, the plateau was 59 ± 23
%CVCmax at Control sites, 57 ± 22
%CVCmax at Keto sites, 18 ± 14 %CVCmax
at TEA sites, and 28 ± 20 %CVCmax at Keto+TEA
sites. During the high hormone phase, the plateau was
56 ± 25 %CVCmax at Control sites, 65 ± 24 %CVCmax
at Keto sites, 16 ± 13 %CVCmax at TEA sites, and 28 ±
19 %CVCmax at Keto+TEA sites. There was a main effect of experimental site on plateau, where plateau
blood flow was lower at TEA and Keto+TEA sites
compared with control and Keto sites (p < 0.01). No effect of phase or interaction effect on plateau were found. The individual responses between low and high hormone phases at Control sites
are displayed in Figure 2D.
Individual plateau responses to pathway inhibition are shown in Figure 2E (next page).
Based on mean individual responses, COX inhibition increased the plateau by 5% during the low

80
hormone phase and 24% during the high
hormone phase (d = 0.5), suggesting a
greater improvement in endothelial function
with COX inhibition during the high hormone phase compared with the low hormone phase. Indeed, there was a medium effect size for the mean difference between
Control sites and Keto sites during the high
hormone phase (d = 0.4), while means of
these sites during the low hormone phase
were similar. Also based on mean individual
responses, EDHF inhibition decreased the
plateau by 69% during the low hormone
phase and 65% during the high hormone
phase, and combined COX+EDHF inhibition decreased the plateau by 52% during the low hormone phase and 45% during the high hormone phase. These mean responses indicate a much
greater reliance (or interdependence) on EDHFs to elicit vasodilation than previously recorded in
other young, mixed-sex cohorts136, 140.
Post-L-NAME Plateau
Figure 2F (next page) shows the post-L-NAME plateau data as mean ± SD. During the
low hormone phase, the post-L-NAME plateau was 16 ± 8 %CVCmax at Control sites, 21 ± 13
%CVCmax at Keto sites, 8 ± 6 %CVCmax at TEA sites, and 10 ± 5 %CVCmax at Keto+TEA sites.
During the high hormone phase, the post-L-NAME plateau was 22 ± 12 %CVCmax at Control
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sites, 16 ± 8 %CVCmax at Keto sites, 9 ± 6
%CVCmax at TEA sites, and 10 ± 5
%CVCmax at Keto+TEA sites. There was a
main effect of experimental site on post-LNAME plateau, where post-L-NAME plateau blood flow was lower at TEA and
Keto+TEA sites compared with control
and Keto sites (p < 0.01). No main effect
of phase or interaction effect was found for post-L-NAME plateau.
Nitric Oxide Contribution to Vasodilation
Figure 2G shows the NO contribution to vasodilation (mean ± SD), calculated using the
equation detailed above (see Methods: Data Analysis). During the low hormone phase, the NO
contribution was 72 ± 13 %NO at Control sites, 63 ± 19 %NO at Keto sites, 51 ± 14 %NO at
TEA sites, and 54 ± 21 %NO at Keto+TEA sites. During the high hormone phase, the NO contribution was 62 ± 16 %NO at Control sites, 75 ± 12 %NO at Keto sites, 42 ± 15 %NO at TEA
sites, and 59 ± 17 %NO at Keto+TEA
sites. There was a statistically significant
interaction effect (phase*experimental site)
for NO-dependent vasodilation (p = 0.03).
During the low hormone phase, the NO
contribution was greater at Control sites
than at TEA sites (p < 0.01) and
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Keto+TEA sites (p = 0.05), but no difference between
Control and Keto sites. During the high hormone phase,
the NO contribution was greater at Control (p = 0.01),
Keto (p < 0.01), and Keto+TEA (p = 0.04) sites compared with TEA sites. Collectively, this suggests COXderived vasoconstrictor prostanoids may negatively affect NO bioavailability during the high hormone phase.
There was a main effect of experimental site, where %NO was lower at
TEA sites compared with all other sites
(p < 0.01). There was no main effect of
phase on NO contribution. There was a
medium-large effect size for %NO between low and high hormone phase Control sites (d = 0.6), where the individual
responses are displayed in Figure 2H. Individual NO-dependent responses to
pathway inhibition are shown in Figure
2I.
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RESULTS: PROJECT 3
Lifestyle behaviors, such as physical activity, sleep, dietary intake, and stress, can impact
endothelial function. This includes alterations to eNOS expression and NO production, as well as
changes in oxidative stress and inflammation. Compared with men, women are more likely to
consume diets higher in plant-derived antioxidants68 but are also less likely to meet recommended guidelines for physical activity and more like to report worse sleep outcomes and greater
stress3, 66, 67. Despite the supported beneficial effects of these behaviors in the literature, they
have not correlated with oxidative stress and inflammation markers in cohorts of women athletes
using OCP, although they have correlated with markers in NC women10, 11. The impact of lifestyle behaviors, such as these, on endothelial function in premenopausal women using OCP warrants further investigation.
The purpose of Project 3 is to preliminarily evaluate the relative impact of potential correlates of endothelium-dependent microvascular dilation and NO bioavailability in premenopausal women taking monophasic, combined OCP for at least three months. The potential impact of
lifestyle behaviors and characteristic/behavioral aspects of OCP use (i.e., duration of use) were
assessed. We hypothesized the magnitude of endothelium-dependent and NO-dependent vasodilation would 1) directly correlate with hours of sleep, hours of moderate and vigorous physical
activity, and quantity of dietary intake of vasculo-protective foods, 2) inversely correlate with
self-reported psychological stress, and 3) inversely correlate with duration of OCP use.
Participant Characteristics
Participant descriptive and hemodynamic information is shown in Table 3A (following
page).
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Table 3A. Participant characteristic information.

Mean ± SD
(n = 12)

Age (y)

23 ± 4

Self-identified race/ethnicity*

2 A / 2 H / 3 NHB / 5 NHW

Duration of OCP Use (mo)

24 ± 29

Height (m)

1.65 ± 0.07

Weight (kg)

66.17 ± 12.14

BMI (kg/m2)

23.9 ± 3.4

Resting Heart Rate (bpm)

73 ± 7

Systolic Blood Pressure (mmHg)

113 ± 6

Diastolic Blood Pressure (mmHg)

71 ± 5

Mean Arterial Pressure (mmHg)

85 ± 5

*A, Asian. H, Hispanic. NHB, non-Hispanic Black. NHW, non-Hispanic White.

Association with Physical Activity
Physical activity was assessed as
total hours of moderate or vigorous intensity physical activity (including hours
from occupational, household, or struc-
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prior to experimental testing. Table 3B displays the correlation between physical activity and
vasodilation responses. Figure 3A shows the relationship between physical activity and NO-dependent vasodilation.
Table 3B. Correlation of Cutaneous Microvascular Vasodilation
Responses with Hours of Physical Activity per Week
Endothelium-Dependent Vasodilation (%CVCmax)

r

p-value

-0.05

0.82

%NO-Dependent Vasodilation

0.36

0.08
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Association with Sleep

number of hours of sleep per night
over the 7 days prior to experimental
testing. Table 3C displays the correlation between sleep and vasodilation
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Vasodilation (%CVCmax)
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tionship between sleep and endothelium-dependent vasodilation.
Table 3C. Correlation of Cutaneous Microvascular Vasodilation Responses with Average Hours of Sleep per Night
Endothelium-Dependent Vasodilation (%CVCmax)

r

p-value

0.34

0.10

%NO-Dependent Vasodilation

0.14

0.51

Association with Stress
Participants were asked to rank how often (1 = never, 2 = rarely, 3 = sometimes, 4 = often, 5 = very often) they felt stress regarding 11 specific categories. Stress below is defined as
the summation of ranked frequency across the 11 categories of stress over the 7 days prior to experimental testing. Table 3D displays the correlation between stress and vasodilation responses.
Figure 3C (next page) shows the relationship between stress and endothelium-dependent vasodilation.
Table 3D. Correlation of Cutaneous Microvascular Vasodilation Responses with Frequency/Severity of Stress per Week
Endothelium-Dependent Vasodilation (%CVCmax)

r

p-value

-0.30

0.15

%NO-Dependent Vasodilation

0.11

0.61
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Association with Acute Dietary Intake
Participants were asked to recall the frequency and quantity of foods grouped by categories of dairy foods, fruits, vegetables, eggs/meats, breads/cereals/starches, beverages, and
sweets/baked goods over the 7 days prior to experimental testing. Correlation between dietary
intake of select food items and endothelium-dependent vasodilation and NO-dependent vasodilation are displayed in Table 3E and Table 3F (next page), respectively.
Table 3E. Correlation of Endothelium-Dependent Vasodilation
with Selected Dietary Intake Variables
Cheese (servings/wk)

r

p-value

0.20

0.36

Eggs (servings/wk)

0.01

0.99

Red Meat (servings/wk)

0.02

0.91

Fruits and Vegetables (servings/wk)

-0.21

0.32

Fruits (servings/wk)

-0.15

0.50

Berries (servings/wk)

-0.13

0.55

Vegetables (servings/wk)

-0.25

0.25
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Table 3F. Correlation of %NO-Dependent Vasodilation with Selected Dietary Intake Variables
Cheese (servings/wk)

r

p-value

0.06

0.77

Eggs (servings/wk)

0.20

0.36

Red Meat (servings/wk)

0.06

0.80

Fruits and Vegetables (servings/wk)

0.22

0.29

Fruits (servings/wk)

0.23

0.27

Berries (servings/wk)

0.17

0.44

Vegetables (servings/wk)

0.19

0.38

Association with Duration of Use
Table 3G displays the correlation between OCP use duration and vasodilation responses.
Table 3G. Correlation of Cutaneous Microvascular Vasodilation Responses with Duration of OCP Use
Endothelium-Dependent Vasodilation (%CVCmax)

r

p-value

0.29

0.18

%NO-Dependent Vasodilation

0.05

0.82

The relationship between duration of use and endothelium-dependent vasodilation was
driven largely by one participant with 108 mo of use and a relatively high plateau values (~76
Figure 3D

ship between duration of use and endothelium-dependent vasodilation with these
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RESULTS: PROJECT 4
There is a gap in the literature regarding the impact of OCP cessation on endothelial
function and NO bioavailability7. If OCP use does cause increases in inflammation and oxidative
stress, a cessation in use may reflect a resolution of endothelial distress. The purpose of Project 4
is to preliminarily assess (via case study) the impact of cessation of monophasic, combination
OCP use on cutaneous microvascular endothelial function and NO bioavailability in one young,
healthy, premenopausal woman. In this case study, we hypothesized that 1) magnitude of endothelium-dependent vasodilation would be greater following cessation of OCP use, and 2) there
would be greater variability in NO-dependent vasodilation when NC compared with using OCP.
Participant Characteristics
Data were recorded from the same premenopausal woman between July 2018 and September 2021. She self-identified racial/ethnic background as non-Hispanic White. She had an unremarkable medical history, was regularly physically active, and was nulliparous across this entire time span. The OCP data set corresponds to months 133-144 of fourth generation OCP use
(0.02 mg EE, 3 mg drospirenone). The NC data set corresponds to months 19-22 following cessation of OCP use. Over the NC testing time frame, average cycle length was 32 d, without a cycle lasting longer than 40 d within the last 10 months. Over the 4 years of assessment, BMI, resting heart rate, and resting blood pressure remained similar. Average participant characteristic information across the OCP and NC data sets is displayed in Table 4A (following page). Data are
shown as mean ± SD.
Within this data set, there are six experimental visits. The first, second, and third time
points correspond, respectively, to a high hormone visit at 133 mo of OCP use, a high hormone
visit at 134 mo of OCP use, and a low hormone visit at 144 mo of OCP use. The fourth, fifth,
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and sixth timepoints refer, respectively, to d 4 of the NC at 19 mo post-cessation, d 16 of the NC
at 20 mo post-cessation, and d 10 of the NC at 22 mo post-cessation.
Table 4A. Participant characteristic information.

Age (y)

OCP
(n = 3 visits)

NC
(n = 3 visits)

26 – 27

29

Height (m)

1.57

Weight (kg)

55.52 ± 1.27

56.12 ± 0.84

BMI (kg/m2)

22.4 ± 0.5

22.6 ± 0.3

Resting Heart Rate (bpm)

68 ± 3

68 ± 4

Systolic Blood Pressure (mmHg)

108 ± 4

107 ± 6

Diastolic Blood Pressure (mmHg)

67 ± 3

68 ± 5

Mean Arterial Pressure (mmHg)

81 ± 4

81 ± 5

Cutaneous Microvascular Vasodilation Responses
Data are presented as mean ± SD. In Figures 4A and 4F, circles represent the time period
during OCP use and triangles represent the NC state following cessation of use. Further, in all
figures, open symbols represent low hormone visits respective to hormonal state, and filled symbols represent respective high hormone visits.
During OCP use, maximal vasodilation averaged 3.10 ± 0.64 flux/MAP. Following cessation of OCP, maximal vasodilation averaged 2.50 ± 0.51 flux/MAP (d = 1.0). This is a ~19%
reduction in average maximal vasodilation from OCP use to NC. Figure 4A shows maximal vasodilation over time. During OCP use, baseline blood flow averaged 10 ± 1 %CVCmax. Following
cessation of OCP, baseline blood flow averaged 28 ± 12 %CVCmax (d = 2.1). This is a ~181%
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increase in average baseline blood flow from OCP use to NC, though there is notably more variability. Figure 4B shows baseline blood flow over time.
Figure 4B.
Baseline Over Time

Figure 4A.
Maximal Vasodilation Over TIme
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During months 133-144 of OCP use, plateau blood flow (i.e., endothelium-dependent
vasodilation) averaged 42 ± 10 %CVCmax. Between 19-22 months following OCP cessation,
plateau blood flow averaged 63 ± 10 %CVCmax. The effect size of the mean difference is d = 2.1.
This is a ~33% increase in average %CVCmax. of the plateau from OCP use to NC. Figure 4C
shows average plateau blood flow across hormonal states. Figure 4D shows plateau blood flow
over time.
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Across the same time frames, average NO-dependent vasodilation was 70 ± 5 %NO during OCP use and 60 ± 15 %NO when naturally cycling. The effect size of the mean difference is
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d = 0.9. Figure 4E shows average NO-dependent vasodilation across hormonal states. Figure 4F
shows NO-dependent vasodilation over time. Notably, NO-dependent vasodilation was similar
between the OCP data points and two of the NC data points (NC, d4 and d10 visits; 70 vs. 68
%NO, respectively). The third NC data point for NO-dependent vasodilation was substantially
lower than the other two (43 % NO) and was recorded on d 16 of the NC.
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Figure 4E.
NO Contribution

Figure 4F.
NO Contribution Over Time
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5 DISCUSSION
This section will discuss 1) major themes of the four completed projects, as well as key
findings from 2) Project 1, 3) Project 2, 4) Project 3, and 5) Project 4. Finally, this section will 6)
provide a revised, working model for the effect of OCP on microvascular endothelial function,
followed by discussion of 7) overall conclusions, 8) implications of the findings, and 9) suggestions for future research.
Major Themes
There were four major themes of the four completed projects. These concepts, and others,
will be discussed in more detail in the sections to follow.
First, NC women in the M/EF phase (48 %CVCmax) appear to have the lowest endothelial
function of the subgroups assessed in this dissertation. Women using OCP have slightly elevated
endothelial function compared with NC women in the M/EF phase, though this may not be statistically significant. For instance, endothelial function was 56-59 %CVCmax during the low hormone phase of OCP use and 56 %CVCmax during the high hormone phase of OCP use. However,
the included case study suggests that within-subject assessments may reveal a negative effect of
OCP on endothelial function (during OCP use: 42 %CVCmax, following cessation of use: 63
%CVCmax) that may be masked by comparisons between independent groups. Further, in response to the submaximal thermal stimulus of 39°C, men have greater endothelium-dependent
vasodilation (71 %CVCmax) than both subgroups of women.
Second, NO-dependent vasodilation is similar between age-matched men (52 %NO) and
NC women during the M/EF phase (52 %NO). However, OCP use may influence NO-dependent
vasodilation during both the low (72-74 %NO) and high hormone (62 %NO) phases. The included case study also revealed that NO-dependent vasodilation was relatively consistent between fourth generation OCP use and following cessation; however, NO-dependent vasodilation
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was more variable during NC. This was expected considering the NC assessments included both
low and high hormone phases, and NO bioavailability varies with estradiol concentration174, 179181

.
Third, the use of OCP appears to be associated with alterations to endothelium-dependent

pathways. Women using OCP demonstrate a greater interdependence on EDHF pathways to
elicit vasodilation (65-69%) than previously investigated young, mixed-sex cohorts (15-30%).
Further, while data from previous samples of young men have suggested that the COX pathway
does not contribute to either baseline blood flow or to the thermal hyperemia response in the
skin, the COX pathway appears to contribute to basal vascular tone, the NO contribution to dilation, and possibly overall endothelial function in women using OCP.
Fourth, throughout this dissertation, there is indication for increased maximal vasodilation with OCP use. This was exhibited by greater maximal vasodilation during the high compared with the low hormone phase of OCP use (p = 0.01) and medium-large effect sizes for 1)
women using OCP in the low hormone phase versus men (p = 0.1, g = 0.6) and 2) OCP use versus cessation of use (d = 1.0). Though not statistically significant, a previous study also showed a
large effect size for maximal vasodilation between low and high hormone phases of OCP use
(low hormone: 1.77 ± 0.19 flux/mmHg; high hormone: 1.92 ± 0.18 flux/mmHg; d = 0.8)21. Despite these differences, we standardized measurements throughout all projects as a percentage of
maximum, as is the standard within the field, to account for inter- and intra-participant variability340. As such, it is possible that absolute differences in microvascular vasodilation responses
may be masked by normalization techniques; however, normalization was crucial to be able to
make comparisons between experimental sites. The underlying cause of increased maximal vasodilation with OCP use is currently unclear. Other studies demonstrating differences in cutaneous

94
maximal vasodilation, such as in aging and diseased populations, have implicated structural differences341-346, though to our knowledge this has not been substantiated experimentally. This includes primarily an assumption of VSMC hypertrophy that may hinder maximal dilator capacity.
Those studies have shown a reduction in maximal vasodilation compared with young, healthy
adults, while our studies indicate an increase in maximal dilation. Therefore, in congruence with
assumptions within the field, this could suggest VSMC atrophy with OCP use. This is supported
by recent indication that OCP use may impair muscle synthesis in response to resistance training347, suggesting decreased anabolic or increased catabolic activities during OCP use. However,
there is no exhibition of VSMC atrophy in other manners with OCP use, such as aneurysm
risk348, 349. Nevertheless, according to Poiseuille’s Law, changes in flow are directly related to
changes in pressure and the radius of the vessel, and inversely related to viscosity of the blood or
length of the vessel. From our data, blood pressure and MAP were similar across phases of OCP
use. Vessel diameter or blood viscosity may be more likely targets for future investigation.
Project 1 Findings
The key findings from Project 1 are: 1) NO-dependent vasodilation is greater in women
during the low hormone phase of OCP use than NC women in their respective low hormone
phase, and 2) there are sex differences in microvascular responses to rapid local heating of the
skin to 39°C.
Comparison of Women in Low Hormone Phases. Findings from this study indicate that
NO-dependent vasodilation differs between women in low hormone phases of the natural menstrual cycle and monophasic, combined OCP use. The NO-dependent vasodilation was ~74
%NO in women using OCP and ~52 %NO in NC women when tested during respective low hormone phases. However, the magnitude of endothelium-dependent vasodilation (i.e., plateau) was
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statistically similar between groups (NC women, 48 %CVCmax; women using OCP, 56
%CVCmax). These data underscore why it is important to directly quantify NO-dependent vasodilation, as solely measuring the magnitude of the plateau may not address the underlying contribution from NO. While NO is implicated as the main contributor to thermal hyperemia in the
skin, several pathways contribute to the response27, 135, 140, 215, 273, 350, 351, and the contribution of
mediating mechanisms has yet to be defined clearly in subgroups of the population, including
women.
The NO contribution was the only portion of the response that reached statistical significance (d = 1.8, p < 0.01) in this comparison. As mentioned, plateau was similar between subgroups of women (NC vs. OCP, mean difference, -8 %CVCmax d = 0.4). Though not statistically
significant, there was a large effect size for the post-L-NAME plateau between groups of women
(NC vs. OCP, mean difference, +8 %CVCmax, d = 0.9). Collectively, the marginally greater plateau and lower post-L-NAME plateau attributed to a greater calculated NO-dependent vasodilation in women using OCP. Additionally, the finding of similar plateau values, yet different contribution from NO, between subgroups of women may indicate an increase in EDHF-mediated
vasodilation in NC women during the M/EF phase. However, objective assessment of these
mechanisms in the cutaneous microvasculature has not been completed. Therefore, while grouping women in various hormonal exposures together increases the inclusion of women in research,
it hinders the ability to delineate effects of endogenous and exogenous hormones on vascular and
endothelial function in women, which may have practical and/or clinical relevance.
These findings also imply that inclusion of both NC and OCP-using women in the same
sample may minimize the ability to accurately interpret data for sex differences, regardless of
testing women during respective low hormone phases. During the original analysis of Project 1
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data (with women of both hormonal exposures grouped together), the data indicated a significant
increase in NO-dependent vasodilation in women (63 ± 17 %NO) compared with men (52 ± 11
%NO). However, the subgroup analysis (when subgroups of women were separated) revealed
that NO-dependent vasodilation between NC women during the M/EF phase and men was nearly
identical within our cohort (NC women, 52 ± 14 %NO). These findings are important and relevant for experimental design, as it is common to group NC and OCP-using women together
within the field, and this may confound results. However, this is also important and relevant for
data interpretation and translation when between or within sex differences are of target interest,
as outcomes may be indicative of neither the distinct effects of endogenous nor exogenous hormones. Although the present analysis was appropriately powered, evaluation within a larger sample may be warranted. It is also warranted to assess this phenomenon during other days of the
placebo pill week of OCP use (days following d 1 - 2 of placebo pills) for confirmation over the
entire low hormone period.
All things considered, exogenous hormone exposure is a regular and common aspect of
life for premenopausal women. Indeed, ~28% of premenopausal women use some form of hormonal contraceptive method, with approximately 14% attributable to OCPs159. Therefore, excluding all women using hormonal contraceptive methods is also not an appropriate solution. We
suggest that participant inclusion be designed with targeted research aims in mind. When research is aimed to assess population-based outcomes, it may be appropriate to include women in
various hormonal states or phases, as this increases external validity. However, when research is
aimed to assess between or within sex differences, especially regarding mechanistic pathways,
hormonal exposures should be taken into consideration and inclusion should be planned accordingly.

97
Sex Differences in Cutaneous Microvascular Function. In this sample of women and
men, there are sex differences in microvascular responses to rapid local heating of the skin to
39°C. We observed greater magnitude of initial peak and plateau in men compared with women
in low hormone phases, suggesting greater sensory nerve-mediated and endothelium-dependent
vasodilation, respectively, in men. Previous studies suggest no sex differences in initial peak27,
270

or in plateau when heating to 39°C 27 or 42°C 26, 270. It is unclear if the study that used a rapid

local heating protocol to 39°C 27 was appropriately powered to detect sex differences; however,
heating to 42°C elicits near maximal vasodilation (~85-95 %CVCmax) in the skin338. Therefore,
near-maximal vasodilation responses may be similar between sexes, but submaximal heating
may reveal physiological sex differences. Potential sex differences in hematocrit352 should not
contribute to the observed differences, as all data are standardized as a percentage of maximum,
which would account for this. Further, while skin temperature may be lower in women during
low hormone phases than in men353, all participants underwent at least 10-15 min of baseline
with sites clamped at 33°C, so observed differences should not be related to differences in starting or change in skin temperature between sexes.
We also observed greater baseline blood flow in men (17 ± 7 %CVCmax) compared with
women (12 ± 5 %CVCmax) in our sample. This agrees with previous report of greater sympathetic regulation of basal blood flow in women compared with men275. Therefore, women may
have to overcome an initial withdrawal of sympathetic regulation that men do not and may, thus,
yield a lower response to a submaximal stimulus.
The magnitude of the post-L-NAME plateau was greater in men than in women, suggesting men were less sensitive to NOS inhibition. However, while men exhibited a greater post-LNAME plateau, they also exhibited a greater magnitude of plateau to local heating, resulting in

98
similar NO-dependent vasodilation in men and NC women. This may further indicate greater
resting blood flow in men compared with women during low hormone phases. These findings
yield important information for future studies using submaximal heating protocols in the skin,
such as heating to 39°C, for interpretation of results.
Project 2 Findings
The key findings from Project 2 are: 1) there is no effect of phase on overall endothelium-dependent vasodilation in women using OCP, 2) there is a greater interdependence on
EDHF to elicit vasodilation in women using OCP than in other young, healthy cohorts, and 3)
the COX pathway contributes to basal blood flow and influences NO pathway contributions to
thermal hyperemia in women using OCP.
Phase of Oral Contraceptive Use. Endothelium-dependent vasodilation was similar between phases of OCP use. This suggests circulating exogenous hormone concentration does not
affect overall endothelial function. Nevertheless, referencing Figure 2D, the individual responses
for endothelium-dependent vasodilation between phases was variable among our sample, where
only one of the twelve participants exhibited virtually no change in endothelial function across
phase. As this dissertation included women using a variety of monophasic, combined OCP, we
considered that EE dose or progestin generation may influence endothelium-dependent vasodilation within our sample; however, there were no clear indications for individual differences based
on EE dose or progestin generation within our sample.
This is the first indication of the effect of OCP phase on endothelial function in response
to a submaximal stimulus within the skin. Within the cutaneous microvasculature, there are also
accounts of marginal differences in near-maximal endothelium-dependent vasodilation21, 308, 309,
where smaller mean differences are more significant, as variability is much lower. Though the
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previous literature regarding OCP use and endothelial function is highly variable, our finding
also agrees with some accounts in the literature regarding conduit vessel endothelial function19,
20, 205, 288, 307, 312, 315

.

There has been minimal previous investigation into the underlying mechanisms of endothelium-dependent vasodilation in women using OCP. This dissertation includes the first direct
quantification of in vivo NO-dependent vasodilation in women using OCP. There was a mediumlarge effect size for NO-dependent vasodilation at control sites between the low and high hormone phases of OCP (72 vs. 62 %NO, respectively, d = 0.7). Previous investigations have attempted to address this question using iontophoresis of ACh, but again, this method elicits dilation with a limited NO-dependent component143, and thus likely does not reflect NO contribution
to microvascular vasodilation. Based on our findings, we hypothesize that the withdrawal of exogenous hormones during the low hormone phase of OCP may temporarily alleviate endothelial
distress (i.e., possibly caused by inflammatory and/or oxidative offenses) and allows greater NO
bioavailability during this time. More details of this hypothesis will be discussed below in the
sub-section discussing the revised working model.
Interdependence on EDHF Pathways. The contribution of EDHF pathways to the initial
peak portion of the response in our sample of women using OCP (54-55%) is similar to that seen
in another young, mixed-sex cohort when heating to 39°C (~50 %EDHF)136. However, EDHF
pathways contributed substantially more to the plateau (i.e., endothelium-dependent vasodilation) in our sample of women using OCP (65-69%) than observed in the other young, mixed-sex
cohort (~30 %EDHF)136. Therefore, direct or indirect VSMC hyperpolarization may contribute
more to microvascular dilation in OCP-using women than cGMP or cAMP second messenger
pathways.
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Surprisingly, our data indicate substantial overlap in mediating mechanisms of vasodilation, as 62-72% of the plateau was also dependent on NO. Nitric oxide may be able to function
as an EDHF by directly activating KCa channels on VSMCs86. These data suggest that in women
using OCP, at least some portion of eNOS-derived NO may be functioning directly as an EDHF,
in a cGMP-independent manner. This is in opposition with other cohorts, where ~50-80% of the
plateau is attributable to NO and ~15-30% is attributable to EDHFs135, 136, 140, suggesting a mechanistic reliance on the classical NO-GC-cGMP signaling pathway in these other cohorts.
Again, OCP use is associated with increased oxidative stress10, 12, 258. Oxidative stress can
reduce GC expression and activity354, 355. Therefore, NO may be functioning as an EDHF in this
population because there is less available GC to interact with. This may result in negative downstream effects within the CV system, as cGMP has numerous targets, in part through PKGs. Cyclic GMP-dependent phosphorylation of PKGs induces VSMC relaxation by inhibiting intracellular Ca2+ release, increases eNOS-derived NO, increases BH4 synthesis, and inhibits platelet adhesion molecules356. Therefore, a physiological role of NO as a direct EDHF may contribute to
CV complications, such as thrombogenesis, in women using OCP by limiting downstream cGMP
signaling.
Further, EETs have previously been reported as independently attributable for approximately 10% of the thermal hyperemia plateau140. It has also been previously proposed that concurrent infusion of Keto, to inhibit COX, and TEA, to inhibit KCa channels, can inhibit EETs.
This is because COX inhibition could permit more available AA for conversion to EETs by
CP450357. In our sample, simultaneous COX and EDHF inhibition led to a 45-52% reduction in
endothelium-dependent vasodilation. Therefore, ~20% of endothelium-dependent vasodilation in
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this cohort of OCP-using women may be attributable to EETs. Again, this suggests a greater reliance on EDHFs in general, but also EETs specifically, compared with previously reported assessments in mixed-sex samples of young, healthy adults. This finding could be validated with
targeted investigation using the CP450 inhibitor, sulfaphenazole140.
Influence of the COX Pathway. Previous investigations suggested that the COX pathway
does not contribute to thermal hyperemia in the skin117, 147. However, these studies were only
completed in samples of young men117, 147. Conversely, in aging populations and hypertensive
adults119, 120, the COX pathway has been shown to influence baseline blood flow, endotheliumdependent vasodilation, and the contribution of NO to dilation.
In our sample of women using OCPs, baseline skin blood flow was greater at COX-inhibited sites compared with all other sites. This has been similarly shown in a cohort of healthy,
middle-aged adults119, while young, healthy mixed-sex cohorts117, 125 show no difference in baseline blood flow with COX inhibition. This suggests COX-derived vasoconstrictive prostanoids,
such as TXA2 or PGH2, may be present and affect basal vascular tone in women using OCP. This
further suggests a basal presence of NO scavengers, such as PGH2 and/or O2-119, 358. There is report of increased basal NO release with EE administration8, which taken together with our findings, could suggest molecular alterations intended to maintain basal vascular tone.
Our data also demonstrate possible interaction of the COX and NO pathways in women
using OCPs. In the low hormone phase, NO-dependent vasodilation was similar between control
and COX-inhibited sites (p = 0.5), but there was a large effect size of NO-dependent vasodilation
between control and COX-inhibited sites (p = 0.2, d = 0.9) during the high hormone phase. Further, EDHF-inhibited sites resulted in similar NO-dependent vasodilation between phases; COXinhibited and EDHF-inhibited sites have statistically similar NO-dependent vasodilation during
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the low hormone phase, but NO-dependent vasodilation was greater at COX-inhibited sites during the high hormone phase (p < 0.01). Although the comparison did not reach statistical significance, COX inhibition increased overall endothelium-dependent vasodilation by 5% during the
low hormone phase and 24% during the high hormone phase on average (d = 0.5). Collectively,
this also suggests COX-derived vasoconstrictor prostanoids may negatively affect NO bioavailability during the high hormone phase of OCP.
Interaction of the COX and NO pathways, such as seen in this study, has previously been
shown in cohorts of hypertensive and healthy aging adults119, 120. While COX inhibition can increase blood flow, co-inhibition of NOS reduces subsequent increases in blood flow119, 120, suggesting COX inhibition can increase NO bioavailability. Again, increases in oxidative stress have
been recorded in women using OCPs10, 12, 258; therefore, this may again reflect a reduction in NO
scavengers with COX inhibition. Women who use OCP also have documented increases in inflammatory biomarkers11, 12, 205, 269. Cyclooxygenase synthesis of vasoconstrictive prostanoids is
induced by inflammation107. Both TXA2 and PGH2 can activate NADPH oxidase in a TP receptor-dependent manner359. Thromboxane receptor-dependent activation of NADPH oxidase is
then further associated with increased ROS generation, decreased cGMP synthesis, decreased
eNOS activity, decreased BH4 synthesis, and increased eNOS uncoupling359. Taken together,
while COX has previously been shown not to influence overall thermal hyperemia in young,
healthy cohorts of men117, 147, it is also possible that the COX pathway may have a role in thermal hyperemia in women or other subgroups of the population. Further, it is possible that COX
may influence underlying mechanisms of dilation in young men as well. Again, this highlights
the importance of directly quantifying the NO contribution to cutaneous microvascular vasodilation.
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Project 3 Findings
The main finding of Project 3 is that there were no statistically significant relationships
between lifestyle behaviors and endothelium-dependent vasodilation or NO-dependent vasodilation in otherwise healthy women using OCP.
Lifestyle Behaviors. The lack of relationships between these variables is important. This
finding in the present study supports data from cohorts of healthy women athletes using OCP10,
11

. In women athletes using OCP, exercise and dietary consumption of antioxidant rich foods did

not correlate with measured hydroperoxides (a marker of oxidative stress), while some measures
were related in NC women athletes10. Additionally, NC women athletes showed a mild inverse
relationship between hsCRP and weekly hours of physical activity, while there was no relationship in OCP users11. Our findings agree with the previous literature in suggesting that OCP use
may result in a pro-oxidant, pro-inflammatory state that is difficult to ameliorate with typically
beneficial lifestyle behaviors. However, our sample furthers this line of research to suggest that
these lifestyle behaviors are largely unrelated to vascular and endothelial function in women using OCP, regardless of their known beneficial effects within the general population.
A few relationships approached statistical significance and may have practical value.
Physical activity showed a moderate positive correlation with NO-dependent vasodilation (r =
0.36, p = 0.08). There was also a moderate positive correlation between sleep and endotheliumdependent vasodilation (r = 0.34, p = 0.10). Further, stress showed a moderate negative correlation with endothelium-dependent vasodilation (r = -0.30, p = 0.15). These relationships agree
with the current understanding of the impact of physical activity, sleep, and stress on endothelial
function. Thus, lifestyle behaviors may have some practical relationship with endothelial func-
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tion, but this may depend on sample attributes. The cohort studied in this dissertation were primarily (11/12) current college students. This could indicate age or education level as mediators
of these relationships. Further, exercise is known to induce temporary, acute increases in inflammation and oxidative stress, though this has been shown to resolve and lead to an overall antiinflammatory and antioxidant condition. The previous studies were completed in competitive
athletes and are, thus, a different subset of women than those studied within this dissertation.
Therefore, activity status, or other related characteristics, may also play a role in the observations.
Duration of Use. In agreement with previous in vivo literature, duration of OCP use did
not correlate with endothelium-dependent vasodilation288, 311. While most previous studies support no relationship, there are data to support increased duration of use is related to increased
markers of oxidative stress following at least one year of use258. Median duration of use in our
cohort was 18 mo, though the range was 3 – 108 mo. Considering the documented timeline of
initial increases in inflammation and oxidative stress with OCP use258, 259, it is interesting that duration of use does not appear to contribute to further decrements. This could indicate an initial
increase in inflammation and oxidative stress followed by subsequent defensive alterations in
molecular pathways. For instance, the literature suggests an increase in basal NO release with EE
administration8, an upregulation in activity through the NO pathway (that is not matched with
vasodilation responses) in OCP users204, and an upregulation in antioxidant enzyme expression
(including catalase and GPx267, 268). Therefore, molecular alterations may compensate for or defend against further increases in inflammation or oxidative stress with prolonged use.
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Project 4 Findings
The key findings from the case study in Project 4 are as follows: 1) endothelium-dependent vasodilation increases after OCP cessation, and 2) NO-dependent vasodilation is generally
consistent before and after cessation of fourth generation OCP use (though there is more variability when NC).
Participant Characteristics. One healthy, premenopausal woman was followed over ~4
years for six experimental testing sessions in total, including three measurements during 11-12 y
of fourth generation OCP use and three measurements ~1.5 y following cessation of use. Over
the 4-y study period, this woman maintained consistent lifestyle behaviors and physiological variables, such as BMI, resting heart rate, systolic and diastolic blood pressure, and MAP. Overall,
this supports other reports of fourth generation OCP having minimal effects on resting hemodynamics, considering their lower androgenic and mineralocorticoid effects compared with other
generations163, 168-170.
Endothelium-Dependent Vasodilation. There was a consistent increase in endotheliumdependent vasodilation following OCP cessation (during use: 42 ± 10 %CVCmax; after cessation:
63 ± 10 %CVCmax). This suggests that even without any evident decrements to physical health
(i.e., no changes in BMI, hemodynamics, medical history, etc.), there was an apparent decrement
in endothelial function during OCP use (33% observed difference). Notably, measured endothelium-dependent vasodilation of ~42 %CVCmax is similar to that seen in populations known to be
at increased risk of cardiometabolic disease, such as non-Hispanic Black or African American
adults27, 47, 272, 273. This may, thus, indicate endothelial distress and acutely increased CV risk in
women using OCP. It is currently unclear what signaling pathways may mediate this difference,
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but assessment of mechanistic changes is warranted, as some findings suggest OCP use at any
time can impact future CV health30.
NO Contribution. The NO pathway does not appear to directly mediate the increase in
endothelium-dependent vasodilation. In this case study, there was a decrease in average NO-dependent vasodilation from OCP use (70 ± 5 %NO) to NC (60 ± 15 %NO), though two of the
three NC data points were similar to those during OCP use. The NC measurements were taken
(in chronological order) on d 4, d 16, and d 10 of the natural menstrual cycle. The NO-dependent
vasodilation averaged 68 %NO on the d 4 and d 10 assessments. The measurement from d 16,
corresponding with a time near ovulation, was markedly lower than the other two measurements
(43 % NO). Other data has suggested lowest endothelial function following the approximate time
of ovulation293. This corresponds with a complex period within the natural menstrual cycle, with
changes in several hormones, including peak testosterone161.
There was more variability in NO-dependent vasodilation when NC, though this was
largely due to the singular data point at NC d 16. Most literature supports changing NO with
changing endogenous estradiol concentration186, 187, and these measurements were not isolated to
one phase of the natural menstrual cycle, so we anticipated greater variability in NO while NC.
NO-dependent vasodilation was consistent through OCP use, including across the one low and
two high hormone phase assessments. Longitudinal studies assessing the impact of OCP use on
vascular and endothelial function are scarce; therefore, it is unclear if this is a feature of fourth
generation progestins (i.e., drospirenone) or universal across combined OCPs.
Maximal Vasodilation. As referred to above in the Major Themes sub-section of this
chapter, there was a ~19% reduction in average maximal vasodilation from OCP use to cessation
of use. The observed 33% increase in average endothelial function (discussed above in this sub-
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section, Endothelium-Dependent Vasodilation) does not appear to be fully dependent on the relative decrease in maximal vasodilator capacity following cessation of use (since all measurements
are expressed at percentage of maximal blood flow). Again, this study revealed no further context for the reason of increased maximal vasodilation with OCP use, but this finding suggests future investigation may be warranted.
Strengths and Limitations. There are strengths and limitations of this case study.
Strengths of this case study include the following. 1) It is the first assessment of endothelial
function across the transition from long-term OCP use to NC. 2) This case study includes assessments at multiple time points before and after OCP cessation. 3) There was consistent health status of the participant over the 4-y span of study. 4) Importantly, it would be difficult to complete
an adequately powered, prospective study aimed at investigating outcomes following OCP cessation after long-term use, especially to the extent demonstrated in this case study (during 133-144
mo of use). Limitations of this case study are as follows. 1) There is low external validity, considering this is a singular account. 2) There is a lack of assessment closer to OCP cessation. 3)
We did not control for hormonal phase across visits. Regardless of the noted limitations, we believe this case study demonstrates relevant information that has previously been undocumented.
Overall, the case study design used in this project was both informative and effective at addressing the aim in question.
Revised Working Model of the Effect of Oral Contraceptives on Endothelial Function
We have used the findings from this dissertation to review our working model for the impact of monophasic, combined OCPs on cutaneous microvascular endothelial function. We propose the following:
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The use of OCP initiates a level of endothelial distress (i.e., possibly inflammatory and/or
oxidative offenses) compared with the natural menstrual cycle. During the high hormone phase
of OCP, bioavailable NO may be in jeopardy of depletion due to these offenses. In return, components of the NO pathway, such as eNOS expression204, may be upregulated with intention to
combat negative side effects of OCPs. However, an impaired redox balance within the environment may result in eNOS uncoupling and, thus, yields lower NO synthesis overall. A withdrawal
of exogenous hormones, such as during the low hormone phase of OCP, temporarily alleviates
endothelial distress and acutely allows greater NO bioavailability during this time.
In addition to this findings presented in this dissertation, this hypothesis is supported by
data showing increased basal NO release and increased vasoconstrictor responses to NOS inhibition in women using OCP29. This hypothesis is further supported by evidence of increased eNOS
expression within the skin, but no concurrent increase in vasodilation responses, in women using
OCP204. Further, this model is congruent with previous reports of paradoxically increased eNOS
expression in accounts of oxidative stress-induced endothelial dysfunction360-363.
Concurrently, we propose that the pro-oxidant and pro-inflammatory environment created
by OCP use alters activity through other endothelial signaling pathways. Chronic inflammation
may induce greater TXA2 synthesis through COX, as well as increased concentrations of PGH2,
because of the general upregulation in COX activity. This increases basal constriction, NO scavenging, and TP-dependent activation of NADPH oxidase. These actions lead to increased ROS
generation, decreased BH4 synthesis, and eNOS uncoupling. Cyclic GMP-dependent vasodilation is also reduced, as NADPH oxidase reduces cGMP synthesis, and oxidative stress can reduce GC expression and activity. There is, thus, less GC for NO to interact with, leading to less
downstream cGMP signaling to effectors. This collectively results in a greater interdependence
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on EDHF pathways to elicit microvascular vasodilation. A simplified schematic of this revised
working model is shown in Proposed Model 3.

Proposed Model 3. Simplified mechanistic schematic of the proposed impact of OCP on endothelium-dependent pathways. Black lines indicate mechanisms supporting vasodilation. Red lines indicate mechanisms supporting vasoconstriction. Dotted lines indicate possible alterations with OCP use. Ca2+, calcium ions. CP450, cytochrome P450 epoxygenase. AA, arachidonic acid. EET, epoxyeicosatrienoic acids. K Ca, calcium-dependent potassium channel. K+, potassium
ions. NO, nitric oxide. BH4, tetrahydrobiopterin. eNOS, endothelial nitric oxide synthase. GC, guanylate cyclase. cGMP,
cyclic guanosine monophosphate. NADPH, nicotinamide adenine dinucleotide phosphate. COX, cyclooxygenase. PGI2,
prostacyclin. AC, adenylate cyclase. cAMP, cyclic adenosine monophosphate. TXA 2, thromboxane. TP, thromboxane reConclusions
ceptor.

In this dissertation, we provide evidence to suggest the following. 1) Nitric oxide-dependent vasodilation differs between women in low hormone phases of the natural menstrual cycle
and monophasic, combined OCP use. 2) The submaximal thermal stimulus of 39°C elicits
greater magnitude of sensory nerve-mediated and endothelium-dependent vasodilation in men
compared with women in low hormone phases, but NO-dependent vasodilation is similar between men and NC women in the M/EF phase. 3) Phase of monophasic, combined OCP use does
not affect magnitude of endothelium-dependent vasodilation. 4) Women using OCP display a
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greater interdependence on EDHF pathways to elicit microvascular vasodilation than previously
studied young cohorts, which may include NO functioning directly as an EDHF. 5) The COX
pathway contributes to basal blood flow and influences NO pathway contributions to thermal hyperemia in women using OCP, unlike previous reports in young men. 6) Lifestyle behaviors do
not appear to contribute to endothelium-dependent or NO-dependent vasodilation in otherwise
healthy women using OCP, though physical activity, sleep, and stress may be promising targets
for future investigation. 7) Endothelium-dependent vasodilation increases after cessation of longterm fourth generation OCP use, while NO-dependent vasodilation is generally consistent before
and after cessation. Our data further the understanding of between and within sex differences in
microvascular endothelial function, especially considering monophasic, combined OCP use.
These data suggest endogenous and exogenous hormones influence mechanisms of endothelial
function, which warrant further targeted investigation. Specifically, OCP use appears to alter mediating mechanisms in the endothelium, which may contribute to acute or long-term CV health in
women.
Implications
Findings from this dissertation have clinical implications for CV health in women using
OCP. The endothelium is a complex feature of human physiology. For instance, the level of intricacy and interaction between endothelium-dependent pathways is highlighted in the findings
from Project 2. To conclude that OCP use may or may not impact overall endothelial function, as
many previous studies have, discounts the multifaceted role and nature of the endothelium and
downstream signaling of endothelial-derived substances. The projects in this dissertation represent an initial step in understanding the impact of OCP use on this complex, physiological net-
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work. As such, the potential impact of OCP use on endothelial function, and consequently vascular function and CV health, necessitates further investigation. Considering the number of women
who have ever used OCP, and the multitude of formulations available, the true impact of OCP
use on CV health in women remains unclear at this time.
Findings from this dissertation also indicate several recommendations for experimental
design or data interpretation within the field of cutaneous microvascular research. First, the completed studies highlight the importance of directly quantifying NO-dependent vasodilation, instead of inferring based on the overall magnitude of the plateau. Second, when research is aimed
to investigate underlying mechanisms of endothelial function or to deduce between or within sex
differences, hormonal exposure of women participants should be considered, and inclusion
should be planned carefully. Further, if the primary outcome is NO-dependent vasodilation, it
would be most appropriate to separate NC women and women using OCP, even if they are being
tested during low hormone phases. Third, when research is aimed to assess overall endotheliumdependent vasodilation, and not further investigate underlying mechanisms or the specific influence of hormonal exposure, it may be appropriate to include women under various hormonal exposures within the same sample. We believe this also applies to population-based studies, where
external validity is of importance for large-scale interpretation. Fourth, when possible, repeated
measures designs may be most effective at determining the effect of OCP on endothelial function, as context may be lost when completing cross-sectional analysis of independent groups. Finally, there appear to be sex differences in cutaneous sensory nerve-mediated and endotheliumdependent vasodilation with the submaximal thermal stimulus of 39°C, which should be kept in
mind for data interpretation.
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Suggestions for Further Research
Findings from the studies in this dissertation indicate several areas for future research.
Various topics for future research have been suggested throughout this dissertation, but the following encompass the most pertinent.
First, concomitant assessment of in vivo cutaneous microvascular endothelial function
and markers of oxidative stress and/or inflammation has yet to be completed in women using
OCP. It is unclear at this time if measures of cutaneous microvascular function and systemic oxidative stress or inflammation are related. As such, it is also unclear if manipulation of oxidative
stress and inflammation pathways would affect in vivo cutaneous microvascular or endothelial
function in this population. Oxidative stress pathways could be assessed using the techniques
used in this dissertation and perfusion of pharmacological agents such as ascorbate (i.e. general
antioxidant)310, tempol (i.e., superoxide dismutase mimetic)47, or apocynin (i.e., NADPH oxidase
inhibitor)27. Salicylate may represent an agent to assess inflammation via intradermal microdialysis364, but as CRP exerts endothelial effects via activation of NADPH oxidase233, apocynin may
also allude to effects of CRP signaling.
Second, gaps remain in our understanding of microvascular endothelial function in NC
premenopausal women. It is unclear if the mechanistic alterations in endothelial function observed in Project 2 are isolated to women using OCP or if NC women may also exhibit differences in the reliance on EDHF or COX pathways in general or across menstrual cycle phases.
Further, there has yet to be a direct investigation of sex differences in underlying pathways of endothelial function in the skin.
Finally, exogenous hormone exposure, including EE dose, progestin generation, and
route of administration, likely have different effects on mechanisms of endothelial function.
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Structured, well-controlled studies assessing the effect of these variables on mechanisms of in
vivo endothelial or vascular function are warranted to fully understand the impact of hormonal
contraceptive methods on CV health in women.
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For lab use only
Date:
Participant ID:

HEALTH HISTORY QUESTIONNAIRE
All information on this questionnaire will be kept strictly confidential. Only individuals involved in this
study will be able to access this information. Your answers to these questions are for research purposes only. Your
answers will not be used to diagnose or treat a disease or condition. If you have questions about any of your answers, you should consult your doctor.

PERSONAL HEALTH HISTORY
 White
 Black/African American
 Hispanic

Name:

Height

Inches:

Weight

Meters:

Resting Blood Pressure
Systolic:
Diastolic:
1.
1.
2.
2.
3.
3.

 Asian
 Pacific Islander
 Other:
__________

Pound:

DOB:
Age:

BMI:

Kilograms:

MAP (calculated):
1.
2.
3.

Do you have, or have you ever had, any of the following (check all that apply):
 Diabetes (type 1 or 2)
 Cancer (and treated with chemotherapy or radiation therapy)
 Chronic pain in arms or legs lasting more than a few days
 History of cardiovascular disease (high cholesterol, stroke, heart attack)
 Nerve damage
 Skin disease (eczema, dermatitis, rash, or irritation lasting more than a few days)
 COVID-19 (as diagnosed by positive test result)
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Major surgeries or hospitalizations in the past 5 years (if you need more room, use the
back)
Year
Reason (briefly explain)

List your prescribed drugs or over-the-counter drugs (if you need more room, use the
back)
Name of Drug
Strength (Dose) if known
Frequency Taken (ex: 2 times
per day)

Allergies to drugs or supplements (if you need more room, use the back)
Name of the Drug
Reaction You Had

HEALTH HABITS
Exercise

Diet

 Sedentary (no exercise)
 Light to mild exercise (climb stairs, walk, play golf; not enough to
break a sweat)
 Occasional vigorous exercise (riding a bike on an even surface, playing doubles tennis, mowing the lawn; enough to break a sweat; less
than 150 min or 2.5 hours per week)
 Regular vigorous exercise (jogging, swimming, playing basketball,
playing singles tennis; more than 150 min or 2.5 hours per week)
Are you on a diet? If yes, briefly describe.

Rank how much salt
you eat

 High

 Medium

 Low
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Caffeine
(check all
that apply)
Alcohol

Rank how much fat
 High
you eat
 None
 Coffee
# cups/cans per day (on average)?

 Medium

 Low

 Tea

 Soda/cola

Do you drink alcohol?
If yes, what kind (beer, wine, cocktails)?

 Yes

 No

About how many drinks do you have per day on average?
About how many drinks do you have per week on average?
 Yes
 Yes
 Year Quit

 No
 No

Tobacco/Nicotine

Do you use tobacco?
Do you use nicotine?
 # of Years

Stress

Do you typically feel under a lot of
 Yes
 No
stress?
About how many hours of sleep do you get each night on average?

Sleep

Do you typically have trouble sleeping?

 Yes

 No

MENSTRUAL CYCLE
If you feel more comfortable, you may elect to answer these questions privately (on
your own) or you may have a female member of the lab team record your information.
Date of last menstruation:

How often do you have a period (every x days)?

Are you taking oral contraceptives (birth control pills)?

 Yes

 No

If yes, please provide the name (generic or name-brand) and dosage.

If yes, please indicate how long you
have been taking this specific pill.

Do you use a hormonal longacting reversible contraceptive (intrauterine device
(IUD), implant, etc.)?

 Yes
If yes, please provide the type/name
(generic or name-brand) and dosage.

 No
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If yes, please indicate how long you
have been using this specific contraceptive.

If you take oral contraceptives or use a long-acting reversible contraceptive, please indicate WHY you began using this method of contraception.

Are you pregnant or breastfeeding?

 Yes

 No

Status of urine pregnancy
test?

 Positive

 Negative

EMERGENCY CONTACT INFORMATION
Name of Emergency Contact(s):

Home Phone:
Cell Phone:
Work Phone:
Email:
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THE COLLEGE STUDENT STRESS SCALE
For the following items, report how often each has occurred over the prior 7 days using
the following scale:
NEVER

RARELY

SOMETIMES

1

2

3

OFTEN

VERY OFTEN

4

5

1. Felt anxious or distressed about personal relationships _____
2. Felt anxious or distressed about family matters _____
3. Felt anxious or distressed about financial matters _____
4. Felt anxious or distressed about academic matters _____
5. Felt anxious or distressed about housing matters _____
6. Felt anxious or distressed about being away from home _____
7. Questioned your ability to handle difficulties in your life _____
8. Questioned your ability to attain your personal goals _____
9. Felt anxious or distressed because events were not going as planned _____
10. Felt as though you were no longer in control of your life _____
11. Felt overwhelmed by difficulties in your life _____
______________________________________________________________________________
12. Compared with the amount of stress you’ve experienced over the past 3 months, was the
amount of stress you felt during the last week more, less, or about the same?
__ More
__ Less
__ About the same
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FIVE_CITY PROJECT PHYSICAL ACTIVITY RECALL
This questionnaire asks about your sleep and physical activity habits over the past 7 days.
1. On average, how many hours did you sleep each night during the last five weekday (Sunday-Thursday) nights? _____ hours
2. On average, how many hours did you sleep each night during the last two weekend (Friday,
Saturday) nights? _____ hours
Next, we will talk about your physical activity during the last 7 days. We are not
going to talk about ‘light’ intensity activities, such as slow walking, light housework, or
non-strenuous sports (bowling, archery, etc.). Please look at this list, which shows examples of moderate, hard, and very hard activities. We engage in many types of activities –
so, if you are not sure where one of your activities fits, please ask me about it.
MODERATE

HARD

Occupational

Delivering mail, patrolling
on foot, house painting, lifting and carrying objects

Heavy carpentry, construction work, physical labor

Household

Raking the lawn, sweeping,
mopping, mowing the lawn,
cleaning windows

Scrubbing floors

Sports

Volleyball, ping-pong, brisk
walking for fun or commute
(~20:00 min/mi), golf, calisthenics

Tennis (doubles), structured
dancing

VERY HARD
Very hard physical labor (digging, chopping, using heavy
tools), carrying heavy loads

Jogging, swimming, tennis
(singles), racquetball, soccer

3. Consider moderate activities. What activities did you do and how many total hours did
you spend during the last 5 weekdays doing these moderate activities or others like them?
Please answer to the nearest half hour. _____ hours // activities:
__________________________________________________
4. Last Saturday and Sunday, how many hours did you spend doing moderate activities, and
what did you do? _____ hours // activities:
__________________________________________________
5. Consider hard activities. What activities did you do and how many total hours did you
spend during the last 5 weekdays doing these hard activities or others like them? Please
answer to the nearest half hour. _____ hours // activities:
__________________________________________________
6. Last Saturday and Sunday, how many hours did you spend doing hard activities, and
what did you do? _____ hours // activities:
__________________________________________________
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7. Consider very hard activities. What activities did you do and how many total hours did
you spend during the last 5 weekdays doing these very hard activities or others like them?
Please answer to the nearest half hour. _____ hours // activities:
__________________________________________________
8. Last Saturday and Sunday, how many hours did you spend doing very hard activities, and
what did you do? _____ hours // activities:
__________________________________________________
9. Compared with your physical activity over the past 3 months, was last week’s physical
activity more, less, or about the same?
__ More
__ Less
__ About the same
10. Please list below any activities which you are uncertain of which intensity to classify
(moderate, hard, or very hard).
Activity:
______________________________
______________________________
______________________________
______________________________

Weekday Hours:
_____________
_____________
_____________
_____________

Weekend Hours:
_____________
_____________
_____________
_____________
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SEVEN DAY FOOD FREQUENCY QUESTIONNAIRE
This questionnaire asks about your consumption of foods and beverages over the past week, which
includes the time from exactly one week ago until the last meal you had before you fill out the questionnaire.
The “How often” columns are for day, week, or rarely/never. We want you to think back over the past week
and tell us how many times (per day/week, if you consume the item every day/week) you consumed each
item. A medium serving is in parentheses.
EXAMPLE: Ate ½ a grapefruit about twice last week.
Ate 1 large hamburger four times last week
Drank 2 cups of whole milk each day
Type of food (Medium Serving)

How Often?
Day

Week

Grapefruit (½)

2

Hamburger, regular (1 patty, 3 oz)

4

Whole milk (1 cup, 8 oz)

Rarely/
Never

Size
S

M

L

2
Check here if not completed:

Type of food (Medium Serving) DAIRY FOODS

How Often?
Day

Whole milk (1 cup, 8 oz)
2% milk (1 cup, 8 oz)
Skim milk (1 cup, 8 oz)
Almond/Soy/Rice milk (1 cup, 8 oz)
Cream whipped (1 Tbsp)
Sour cream (1 Tbsp)
Coffee cream (1 Tbsp)
Ice cream (½ cup)
Low fat ice cream (½ cup)
Frozen yogurt (½ cup)
Yogurt (1 cup)
Low fat yogurt (1 cup)
Cottage cheese (½ cup)
Cream Cheese (1 oz)
Low fat cream cheese (1 oz)
Other cheese (1 slice or 1 oz)
Low fat cheese (1 slice or 1 oz)

Week

Rarely/
Never

Size
S

M

L
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Margarine (1 tsp)
Butter (1 tsp)
Reduced fat margarine (1 tsp)
Check here if not completed:
Type of Food (Medium Serving) FRUITS, FRUIT JUICES

How Often?
Day

Raisins (1 oz or small box)
Grapes (20)
Prunes (½ cup)
Banana
Cantaloupe (1/4 melon)
Watermelon (1 slice)
Apples, applesauce or pears (1 fresh, ½ cup)
Dried apples (1 oz)
Apple juice (½ cup)
Orange
Orange juice (½ cup)
Grapefruit (½ cup)
Grapefruit juice (½ cup)
Other fruit juices (½ cup)
Strawberries – fresh, frozen, or canned (½ cup)
Blueberries - fresh, frozen or canned (½ cup)
Blackberries - fresh, frozen or canned (½ cup)
Raspberries - fresh, frozen or canned (½ cup)
Peaches (1 fresh, ½ cup canned)
Apricots (1 fresh, ½ cup canned)
Plums (1 fresh, ½ cup canned)
Honeydew melon (1/4 melon)
Avocado (1)

Week

Size
Rarely/
Never

S

M

L
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Check here if not completed:
Type of food (Medium Serving) VEGETABLES, VEGETABLE
JUICE

How Often?
Day

Tomatoes (1)
Tomato juice (½ cup)
Tomato sauce (½ cup)
Spaghetti sauce (½ cup)
Red chili sauce, taco sauce, or salsa (1 Tbsp)
Tofu or soybeans (3-4 oz)
String beans, green beans (½ cup)
Broccoli (½ cup)
Cabbage (½ cup)
Cole slaw (½ cup)
Cauliflower (½ cup)
Brussels (½ cup) sprouts
Carrots raw (½ carrot or 2-4 sticks)
Carrots, cooked (½ cup)
Corn (1 ear or ½ cup frozen or canned)
Peas (½ cup fresh frozen or canned)
Lima beans (½ cup fresh frozen or canned)
Mixed vegetables (½ cup)
Beans or lentils, baked or dried (½ cup)
Summer or yellow squash (½ cup)
Winter squash (½ cup)
Zucchini (½ cup)
Yam or sweet potato (½ cup)
Spinach (cooked ½ cup, raw 1 cup)
Iceberg lettuce, romaine or leaf (1 cup)
Celery (4” Stick)
Beets (½ cup)
Green, Red, Yellow peppers (½ cup)
Onions (½ cup)
Alfalfa sprouts (½ cup)

Week

Size
Rarely/
Never

S

M

L
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Mushrooms (½ cup)
Kale, mustard, or chard greens (½ cup)
Vegetable, vegetable beef, minestrone or tomato soup (1 cup)
Check here if not completed:
Type of food (Medium Serving) EGGS, MEATS, ETC.

How Often?
Day

Eggs (2)
Chicken or turkey, roasted or broiled with skin (3-4 oz)
Chicken or turkey, roasted or broiled skinless (3-4 oz)
Chicken fried with skin (3-4 oz)
Bacon (2 slices)
Hot dogs (2)
Low fat hot dogs (2)
Sausage (2 patties or 2 links)
Bologna (1 slice)
Other processed luncheon meat (1 slice)
Liver (3-4 oz)
Hamburger, regular (1 patty, 3-4 oz)
Hamburger, lean (1 patty, 3-4 oz)
Meat loaf (3-4 oz)
Pork, chops, roasts (3-4 oz)
Lamb (3-4 oz)
Beef, roast, steak (3-4 oz)
Beef stew with vegetables (1 cup)
Ham (3-4 oz)
Tuna fish (3-4 oz)
Tuna salad (½ cup)
Fish, baked or broiled (3-4 oz)
Fish, fried or fish sandwich (3-4 oz)
Shrimp, Lobster, scallops
Pizza (2 slices)
Mixed dishes with cheese (1 cup)
Lasagna or meat pasta dishes (1 cup)

Week

Size
Rarely/
Never

S

M

L
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Check here if not completed:
Type of food (Medium Serving) BREADS, CEREALS, STARCHES

How Often?
Day

Cold breakfast cereal (1 cup)
Cold breakfast cereal – fortified (1 cup)
Cooked oatmeal (1 cup)
Other cooked breakfast cereal (1 cup)
White bread (1 slice)
Pita bread (1 piece)
Whole wheat bread (1 slice)
Flat Bread (1 piece)
English muffin (1)
Bagel (1)
Dinner roll (1)
Hamburger or hot dog bun (1)
Muffin (1)
Biscuit (1)
Corn bread, corn muffin (1)
Brown rice (1 cup)
White rice (1 cup)
Spaghetti noodles (1 cup)
Macaroni noodles (1 cup)
Other pasta noodles (1 cup)
Bulgar, kasha, couscous (1 cup)
Pancakes or waffles (2)
Potatoes, French fries or fried (1/2 cup)
Potatoes, baked or boiled (1 cup)
Mashed potatoes (1 cup)
Potato chips, or corn chips (small bag or 1 oz)
Saltine crackers (5)
Saltine crackers, low sodium (5)
Saltine crackers, fat free (5)
Other crackers (5)

Week

Rarely/
Never

Size
S

M

L
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Other crackers low fat (5)
Check here if not completed:
Type of food (Medium Serving) BEVERAGES

How Often?
Day

Week

Rarely/
Never

Size
S

M

L

Regular soft drink (1)
Diet Soft drink (1)
Caffeine free soft drink (1)
Caffeine free, Diet Soft drink (1)
Lemonade or other non-carbonated drink (1 glass, bottle or can)
Water (1 cup)
Coffee (1 cup)
Decaffeinated coffee (1 cup)
Tea (1 cup)
Herbal tea (1 cup)
Beer (1 glass, bottle, or can)
Red wine (4 oz glass)
White wine (4 oz glass)
Whiskey, gin, or other liquor (1 drink or shot)
Check here if not completed:
Type of food (Medium Serving) SWEETS, BAKED GOODS, MISC.

How Often?
Day

Chocolate (1 small bar or 1 oz)
Candy bar (1 small bar)
Candy without chocolate (1 oz)
Cookies, home baked (2)
Cookies, ready-made (2)
Brownies (2)
Doughnuts (2)
Cake, home baked (1 slice)
Cake, ready-made (1 slice)
Sweet roll, coffee cake, or other pastry ready-made (1 serving)
Sweet roll, coffee cake, or other pastry home baked (1 serving)

Week

Rarely/
Never

Size
S

M

L
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Pie, homemade (1 slice)
Pie, ready-made (1 slice)
Jam, jelly, preserves, syrup, or Honey (1 Tbsp)
Peanut butter (1 Tbsp)
Popcorn (1 cup)
Popcorn, air popped (1 cup)
Nuts (small, packet or 1oz)
Bran, added to food (1 Tbsp)
Chowder or cream soup (1 cup)
Oil and vinegar dressing (1Tbsp)
Mayonnaise or other creamy salad dressing, regular (1 Tbsp)
Mayonnaise or other creamy salad dressing, fat free (1 Tbsp)
Mustard dry or prepared (1 tsp)
Salt (1 shake)
Pepper (1 shake)

Can you think of any food or drink that you had in the past week that was not included in
this form? If so, what was it? What was the amount? How many times did you have it this
past week?
Check here if not completed:
Type of food (Medium Serving)

How Often?
Day

Week

Rarely/Never

Size
S

M

L

